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INTRODUCTION 
 Cancer of the  ovary is the 9
th
 most common cancer in the world :both sexes put 
together and the 7
th
 most common cancer among women in the world, (1).Cancer 
ovary is  a lethal female cancer ,because due to its insidious and vague clinical 
presentation with no established screening method for its detection and  two third 
of cases presenting as advanced disease at presentation it has the highest fatality 
to case ratio of all female cancers ,it is the most challenging female cancer to treat 
.(2)cancer ovary is the third most common female cancer in India next to cancer 
of the breast and cervix ,and the economic burden imposed for its treatment in a 
resource constraint country like ours will be a huge challenge   (3),It is accepted 
that  Epithelial ovarian cancer constitute about 90 % of all ovarian cancers with  
Germ cell tumors ,sex cord stromal cell tumors, other rarer  tumors and metastatic 
tumors making up  the rest .   Epithelial ovarian cancer is considered a disease of 
the old as non epithelial tumors is to thought to be more commoner among the 
young.  Although most of the literature combines clinical features and treatments 
of epithelial with non-epithelial tumors, these need to be studied separately. It is 
also not clear how often epithelial tumors affect young women and whether the 
described bi-modal age distribution clearly separates out epithelial and non-
epithelial tumors.(4) It is the aim of this Observational study to look at the 
clinico-pathologic Pattern in women 40 years and below with ovarian cancer, and 
compare the survival outcome of Epithelial and non epithelial cancer based on the 
stage, Histology, Residual tumor and chemotherapy given prior or after surgery 
effect treatment outcome. 
  
 
AIMS and OBJECTIVES 
 
 
1) To look at the clinico-pathologic patterns, in women 40 years and below, with 
ovarian cancer. 
 
2)  To compare the survival outcome of epithelial and non-epithelial cancer in young 
women. 
 
3) To determine the factors associated with survival and recurrence after treatment 
for ovarian cancer in young women. 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Epidemiology: Cancer Ovary is the  7th most common cancer among women 
,in fact in the west the sixth most common cause of death among women  
(5).According to  WHO –International agency for Research on cancer 2012 report 
there were 238719 case of ovarian cancer detected forming age standardized  
incidence  rate of  6.1% with 151905 death forming age standardized  mortality 
rate of 3.8%.As things stands global result shows wide variations in the incidence 
rate of ovarian cancer ,the lowest rate are seen in china and the highest rates are 
seen in Russian federation an United Kingdom(6).  
In India it is projected that there will be 33,218 ovarian cancer case in 2015, 
against the projected estimate of 30,482  ovarian cancer case in 2010, as a study 
done during 2004-2005  showed that it  forms about 1.7 to 8.7  percents  of all 
female cancers  in various urban and rural population based registries of the 
National Cancer Registry program( ICMR).(3).over the last 15 years  survival of 
treated ovarian cancer cases in the US (United states) shows modest 
improvement(6) ,but there is a difference in treatment quality  and survival pattern 
due to  economic disparity among different people group (7) The age distribution 
of epithelial ovarian cancer is that; peak incidence is found in the 56 to 60 age 
group where as more than 70 % of Germ cell tumors are found in the younger age 
group in the first and second decade of life .90 % Epithelial Ovarian Cancer are 
the sporadic form ,and  about 10 % of ovarian cancer occur in women are the 
hereditary type ,susceptibility conferred  due to  defective genes , The hereditary 
ovarian cancer occur roughly 10 years earlier than those of the sporadic type , the 
much studied and documented hereditary  Epithelial ovarian cancer are  
associated with mutations in the  BRCA1 and BRCA2 genes,  these mutated 
genes being found in chromosome 17 and 13 respectively. Though according to 
western statistics germ cell and sex cord stromal cell tumors form about 5 to 8 % 
of  ovarian cancer , literature review shows that the incidence of Germ cell tumor 
is higher in the  Asian and African population constituting about 15 % of all 
ovarian cancers and  Epithelial ovarian cancer forming  about 80 % of all 
malignant ovarian cancer .A study of the histological distribution of ovarian 
cancer seen in various  studies indicate that  that serous type of ovarian cancer is 
the commonest histological type  making up 75to  80 % of epithelial cancer 
,mucinous, makes  up 10% ,and clear cell, Brenner and undifferentiated type ,each 
representing less than one percent of epithelial cancers, mucinous  epithelial 
cancer could be the commoner type among the younger age group , it has been 
hinted that the increase incidence of mucinous type of ovarian cancer could be 
due to relative increase use of oral contraceptive in the past few decades among 
women .It is believed that Epithelial ovarian cancers arise from either the surface 
epithelium of the ovary or from its inclusion cysts within the ovary .Of late there 
has been an increase in the understanding of the molecular pathogensis of  ovarian 
cancers , there could be two ways for the development of a of serous ovarian 
cancer resulting in two different types of cancers, one  which is low grade slow 
growing type originating from  the coelomic or modified mesothelium, the serous 
borderline tumor and low grade serous tumour belong to this group ,there is a 
growing evidence to suggest that high grade serous cancers arise from the fimbrial 
end of the fallopian tube.The type 1 low grade serous tumor are genetically stable 
and are characterized by mutations in KRAS and BRAF . The  high grade type 11 
serous tumor are rapidly growing , highly aggressive tumor that lack well defined 
precursor lesions; most are advanced  stage at , or soon after ,their inception and 
are genetically unstable and they harbor p53 mutation(tumor protein p53 , a 
cellular tumor antigen encoded by TP53 gene, a tumor suppressor gene ) .It has 
often been assumed that that many ovarian cancers are detected late due to its 
vague presentation, but this could be far from the truth as the cell of origin and the 
behavior and the  type 11 ovarian cancer are indeed different and the starting of 
the disease and its clinical manifestation could be very short  .(8)It is also 
assumed from findings of previous studies that the stage matched survival rate in 
the younger age group as compared with those in the older age  is better for 
Epithelial ovarian cancer .(9)  
 
  
 Pathology: 
There are four histogenetic categories of ovarian tumours: 
1. Surface epithelial stromal tumour (65-70%) 
2. Sex cord stromal tumours  (15-20%) 
3. Germ cell tumours( 5-10%) 
4. Metastatic tumours  
 
Table: 1 Classification of ovarian tumors 
EPITHELIAL OVARIAN TUMOURS   
HISTOLOGIC TYPES  CELLULAR TYPE  
1. SEROUS  Endosalpingeal 
A. Benign  
B. Borderline  
C. :Malignant  
2. MUCINOUS Intestinal,Endocervical  
A. Benign.  
B. Borderline  
C. Malignant  
3. ENDOMETRIOID Endometrial 
A. Benign  
B. Borderline  
      C. Malignant  
4. CLEAR CELL Mullerian 
A. Benign  
B. Borderline   
C. Malignant  
5. BRENNER Transitional  
A. Benign  
B. Borderline proliferating  
C. Malignant  
6. Mixed epithelial type Mixed 
A. Benign  
B. Borderline  
      C. Malignant  
7. UNDIFFERENTIATED May be anaplastic 
8. UNCLASSIFIED  
From seroy SF,Sobin LH . INTERNATIONAL HISTOLOGICAL CLASSIFICTION OF TUMOURS .9 Histological typing off 
ovarian tumors.Geneva,Switzerland:World Health Organization,1973,  
 Benign serous cystadenoma constitute about half of all of all ovarian serous tumour  
Serous tumour of Low malignant potential makes up about 15% of all serous ovarian 
neoplasm-micropapillary pattern , stromal microinvasion and , extraovarian disease are 
features of borderline serous tumour , with extra ovarian disease the non invasive implants 
can be divided into the epithelial and desmoplastic types and the invasive form although 
uncommon can progress and form metastastatic implants which may progress  as a 
proliferative disease leading to intestinal obstruction and death (10)(11) 
 Serous carcinoma  accounts for 35 to  % of all serous ovarian neoplasm , and 
approximately 75% of ovarian surface epithelial –stromal carcinomas .The high grade 
(grade 2 to 3 ) serous carcinomas are the most common surface epithelial carcinomas and 
are associated with p53 mutations and somatic or germ-line abnormalities of BRCA1 and 
BRCA2 . 
Mucinous tumors accounts for about 15% of  surface epithelial neoplasm of the ovary, 
80% of all are benign unilocular cystadenomas , they occur in all age group , but more 
freguently so in the reproductive age group .   
Borderline Mucinous tumour account for 15%  of all mucinous ovarian tumour  of 
intestinal type, the endocervival type of mucinous borderline tumor are bilateral 40% of the 
time . 
Mucinous Carcinoma, intestinal type account for less than 10% of all mucinous ovarian 
neoplasms. 
Mucinous tumour with pseudomyxoma peritonei- most of these tumours are metastases 
from primary mucinous tumor of the vermiform appendix  
 Endometrioid  tumour, and low malignant potential endometriod tumours are entities . 
Endometrioid carcinoma of the ovary is comparable to grade 1 or 2 endometrioid 
adenocarcinoma of the uterus.associated with endometriosis 40% of the time and with 
primary endometrioid cancer of the uterus 20% of the time  
Clear cell Carcinomas – occur in the 5th and 7th decade, it could be associated with 
endometriosis, and may be associated with paraneoplastic hypercalcemia or pelvic venous 
thromboses. 
Transitional cell tumour – they are uncommon, forming about 3% of all epithelial stromal 
tumors , the benign, borderline and carcinomas can be seen.  
Undifferentiated Epithelial tumors lacks histologic features of a specific mullerian cell 
type. 
Mixed Surface epithelial tumors have two or more different histologic cell types. 
Sex cord stromal cell tumor demonstrate ovarian, testicular, or a mixture of ovarian and 
testicular cell differentiation ,manyof this subtype express Inhibin , which could act as a 
tumor marker. Granulosa cell tumour is the commonest sex cord cell tumor ,it can occur in 
any age group but more commonly at the  mean age of 52.call-exner bodies are 
characteristic of granulosa cell tumor,juvenile granulosa tumour in 90% of the time occur 
in females younger than 30 years  
Sertoli leydic cell tumour commonly occur in women in their mid -20s . it can occur at a 
very young age as well as even in the seventh decade of a women’s life  .one third of 
sertoli –leydig cell present as virilization .Sex cord tumor with annular tubules , 
gynandroblastoma and Fibroma-thecoma , and sclerosing stromal cell tumours are other 
stromal cell tumors . steroid cell tumours not otherwise specified , leydig cell tumours and 
stromal luteomas also come under sex cord stromal cell tumors.  
 
Sex Cord—stromal Tumors 
1. Granulosa-stromal cell tumors 
A. Granulosa cell tumor 
B. Tumors in thecoma-fibroma group 
1. Thecoma 
2. Fibroma 
3. Unclassified 
2. Androblastomas; Sertoli-Leydig cell tumors 
A. Well-differentiated 
1. Sertoli cell tumor 
2. Sertoli-Leydig cell tumor 
3. Leydig cell tumor; hilus cell tumor 
B. Moderately differentiated 
C. Poorly differentiated (sarcomatoid) 
D. With heterologous elements 
3. Gynandroblastoma 
4. Sex cord tumour with annular tubules  
5. Sex cord stromal tumors, unclassified 
6. Steroid cell tumours 
    A.Stromal luteoma  
    B. cell tumor Leydic  
    C.Steroid cell tumor, not otherwise classified   
Source: Berek & Novak’s gynaecology, fifteenth edition  
 
Germ Cell tumors  - arise from the primordial germ cells of the ovary , 
Dysgerminomas, immature teratomas, and endodermal sinus tumour are common type of 
germ cell tumour, Gonadoblastoma , embryonal carcinoma are other type of GCT, mixed 
germ cell tumors are quite common too. 
  Histologic Typing of Ovarian Germ Cell Tumors 
1. Primitive germ cell tumors    
A. Dysgerminoma                             
B. Yolk sac tumor                                       
C. Embryonal carcinoma                               
D. Polyembryoma                                            
E. Non-gestational choriocarcinoma                   
F. Mixed germ cell tumor                           
2. Biphasic or triphasic teratoma             
A. Immature teratoma                                  
B. Mature teratoma                                      
1. Solid                                                         
2. Cystic                                                       
        a. Dermoid cyst                                    
        b. Fetiform teratoma (homunculus)        
D. Carcinoma  
          E. Melanocytic 
F. Sarcoma 
          G. Sebaceous tumor 
H. Pituitary-type tumor 
 I. Others  
 
3. Monodermal teratoma and somatic-type associated with dermoid cysts 
A. Thyroid tumor 
     1. Struma ovarii 
                  a. Benign 
                  b. Malignant 
 B. Carcinoid 
 
World Health organization classification of tumours, Pathology and and genetics of of 
tumour of  breastand female organs .Lyon :IARC press,2003  
 
 
 
 
 Table No: 2 Germ cell tumor characteristics 
Source: atlas geneticsoncology.org 
Subtype Frequency of 
 OGCT 
 
Benign/ 
Malignant 
Uni-or  
Bilateral 
Tumour markers expressed Metastases 
 Route 
Dysgerminoma 35-59% Malignant  10-15% are  
bilateral  
Serum lactic  
dehydrogenase   
Serum hCG 
Lymphatic 
 System 
Endodermal 
 Sinus tumour  
(EST) 
20% Malignant Usually  
Unilateral  
AFP 
(commonly), 
alpha 1- 
Antitripsin 
 
 
Intraperit 
oneally and 
 hematog 
enously  
Embryonal  
carcinoma  
Rare  Malignant  Usually  
Unilateral 
AFB and hCG Intraperitoneally 
Polyembryoma  Rare    AFB and hCG  
Choriocarc 
inoma  
Very rare  Malignant Usually  
Unilateral 
hCG  
Teratoma  Immature 
 account for 20%  
% GCT 
Benign or 
Malignant 
12-15% 
Are bilateral  
Immature tera 
Toma some 
Times secrete  
AFP,LDHand 
And CA 125. 
 
Mixed GCT 10-15%  Depends on 
 the cell type  
present  
 Depends on the 
 cell type present  
 
 
 Miscellanous ovarian tumors are paraganglioma:myxoma:small cell carcinoma, 
hypercalcemic type:small cell carcinoma,pulmonary and large neuroendocrine carcinomas 
.  
Secondary tumors of the ovary (Metastases)include, carcinoma,lymphomaor leukemia, 
melanoma , and sarcoma , the colon and breast are other  common sites to metastasize  
to the ovary. 
 Fallopian tube carcinomas and peritoneal cancers are treated the same as ovarian cancer 
and evidence suggests that these disease have common pathogenesis and maybe initiated 
in the fallopian tube(8) 
 
 Results of studies of incidence, histologic, patterns, prognosis and outcome of 
Epithelial ovarian tumor in the last 3 to 4 decades.  A study done in  France 
1979:showed that fertility sparing surgery was feasible for young reproductive 
women (12)  
 Outcome of epithelial ovarian cancer in women under 40 years of age treated 
with platinum-based chemotherapy.1999(13)  
Results:These results suggest that there are biological differences in the behaviour of 
serous carcinoma of the ovary in women of reproductive age compared with older women 
 Clinical features of epithelial ovarian cancer in young reproductive women a study done 
in Japan 1995 showed that the incidence of mucinous cystadenoma in women below 40 
years was higher than that found in above 40 years 
 Clinical characteristics and prognosis of epithelial ovarian cancer in young women a 
study done in china over a period of 13 years(1980-2003) the result of their study showed 
that serous adenocarcinoma was the commonest cancer (56%) followed by mucinous 
adenocarcinoma (30.9%)followed by well differentiated tumor(25.4%) and moderately 
differentiated (15.5%) and poorly differentiated tumor , mostly with unilateral 
involvement of the ovary, carrying a good prognosis with fertility preserving surgery 
found to be safe for stage 1a and grade 1 disease , and they found out that pathological 
grade and residual tumor size were independent prognostic factor 
Demographic clinical and prognostic characteristics of primary ovarian, 
peritoneal and tubal adenocarcinomas of serous histology — A prospective 
comparative study(14)  
Result: Primary serous peritoneal cancer has the shortest overall survival among 
the three,  
This study was the largest prospective study comparing primary peritoneal, 
ovarian and fallopian tube carcinomas of serous histology 
 There is an increased  risk of developing serous primary peritoneal cancer depending on  
the parity and obesity of the individual  . 
Outcomes of malignant ovarian germ-cell tumors treated in Chiang Mai University 
Hospital over a nine year period.(15)  This was a clinico- pathological study with survival 
pattern .of the 72 cases recruited,the mean age was 21.6 years and 11.8% were pre-
menarchal . The two most common symptoms were pelvic mass and pelvic pain. Two-
thirds of the studied patients presented at an early stage. The common histology in 
descending order of frequency were: 1. immature teratoma (34.2%) 2. endodermal sinus 
tumor (28.9%),3. dysgerminoma (25%),4. mixed type (10.5%) and 5.choriocarcinoma 
(1.3%). Treatment with fertility sparing operations and adjuvant chemotherapy with a 
BEP regimen showed a good outcome. An advanced stage was found to be prognostic 
factor for recurrence. 
Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: 
A 10-year study in a tertiary hospital of eastern India(16) 
The aim of this study was to find morphologic pattern of ovarian in different age 
group along with bilaterality. They found out that benign disease was common in 
the 20-40 age group, with earlier presentation of malignant tumour at at 40-50 age 
group. The histological types seen idecreasing order was 1.serous cystadenoma 
(29.9%),2. mature teratoma (15.9%) 3. mucinous cystadenoma (11.1%).60.9% of 
the malignant tumour were the epithelial type serous cystadenocarcinoma forming 
11.3% of all the epithelial malignant tumor. 
Regarding bilaterality Metastatic tumors were found to involve the bilateral 
ovaries in 72%, while 49.5% of malignant serous tumors were bilateral. 
Borderline serous tumors showed bilateral involvement more commonly (27.4%) 
than borderline mucinous tumors (15.7%). Most of the malignant tumors 
presented as stage III (60%) or stage II (20%) disease. The overall survival rate 
was 85% for stage I tumors, 65% for stage II, 30% for stage III and 15.5% for 
stage IV tumors. 
To summarize the various studies it appears that for low stage disease 
conservative surgery yields good result and as far as the common histology in the 
young women results are concern results are conflicting as in some studies 
mucinous tumor seems to be more and other studies showing serous histology as 
the common pathology. The prognosis for stage and histology matched disease 
could be better in the young and there could be a difference in the biological 
behaviour of serous carcinoma in younger women. A study of the clinicol-
patological pattern and outcome of primary peritoneal, ovarian and fallopian tube 
serious carcinoma showed worse prognosis for primary peritoneal cancer. A 
number of studies of the borderline tumor underscore the importance of proper 
pathological staging of each tumor and the importance of sub-classification of the 
extra-ovarian disease to invasive or non invasive type as the invasive type has the 
propensity for progress  forming peritoneal implants and progressing to 
widespread intra-peritoneal disease which may lead on to bowel obstruction and 
death.  
 
Clinical features:  More than 80% of of ovarian cancer are seen in postmenopausal 
women, 56 to 60 years is the peak age for invasive EOC. About 30% of ovarian tumour in 
postmenopausal women are malignant, whereas only about 7% of malignant ovarian tumor 
are malignant in premenopausal women. 
The average age for borderline tumor to occur is 46 years .  
 
Etiology :  Broadly speaking ovarian cancer genesis is associated with low parity and 
infertility. Endometriosis,polycystic ovarian syndrome, use of an intrauterine devise ,and 
cigarette smoking(for mucinous carcinomas) are also known risk factors too (17) 
(18),)factors that are associated with  decrease risk include :previous pregnancy ,history of 
breast feeding ,oral contraceptives use, an tubal ligation . Although a variety of 
epidemiologic variables like increased talc use and milk consumption are linked with 
ovarian cancer, and decreased risk associated with tubal ligation ,but none is as strongly 
correlated as prior reproductive history . As far as prevention is concern oral contraceptive 
pills usage is the only chemo-preventive measure identified (17) 
 
Prevention:  Ovarian cancer is seen frequently among women with infertility or low 
parity. Having one child reduces the risk of ovarian cancer by 30 to 40 %. Oral 
contraceptive pills usage for 5 years or above confers a relative risk reduction of 50 %. 
Bilateral salpingo-oophorectomy significantly reduce the risk of ovarian cancer in the high  
risk individuals, but does not totally eliminate it, as the entire peritoneum lining is still at  
risk. 
 
Screening: Randomised control trial of ovarian cancer screening using a strategy that 
included sequential CA 125 and transvaginal ultrasound has been found to increase median 
survival. Annual transvaginal ultrasound screening has been found to decrease disease 
stage at detection and increase case specific ovarian cancer survival in a recent trial 
involving 25,327 women. In spite of this, there is no established screening method in place 
for ovarian cancer. 
The multimodal approach for screening using imaging and a tumor marker is promising. 
Tumor markers are molecules or substances produced by or in response to neoplastic 
proliferation,that enter the circulation in detectable amounts. They indicate the likely 
presence of cancer and provide information about its behavior. For screening protocols, the 
value of the marker depends on its sensitivity (proportion of cancer detected by a positive 
test) and specificity (proportion of those without cancer identified by negative test). The 
most limiting factor is a lack of specificity for most tumor markers and a low positive 
predictive value. However, tumor markers have an important role to play for differential 
diagnosis, screening, determining therapeutic efficiency, detecting recurrences and 
predicting prognosis. 
A variety of imaging modalities are in use to identify the morphological characteristics of 
cancer. These features may not be highly specific but may serve as a sensitive marker.  
Detailed tumor morphology can be quantified for use in a variety of scoring systems.   
The ultrasound features which are used for scoring are:  1. Multilocularity, 2 .Bilaterality  
3. Solid areas 4. Ascites and 5. Intra-abdominal  metastasis.   
Different screening strategies may incorporate 1. CA 125 and Ultrasonography,  
2. Ultrasonography and OVA1, 3. Risk of Malignancy Index (RMI).  
RMI I gives a score of 0 for no feature and a score of 1 for I feature,, and score of 3 if more 
than I feature appreciated. This scoring system, conceptualized by Jacobs et al in 1990, 
takes into account the ultrasound score (U), the menopausal state (M) and, the absolute 
CA125 value in U/L.  RMI = U x M x CA125 and a score > or = to 200 gives a sensitivity 
of 85% and specificity of 97% for predicting malignancy   
 
      
  Table 3.  Risk of malignancy Index (RMI)  
VARIABLES FINDINGS PROCEDURE 
Menopausal status , has the 
women had no period for a 
year or more? 
 
 
 
Is she 50 or older with a 
previous hysterectomy 
PremenopausaI 
 
 
Assign 1 point 
Postmenopause Assign 4 points  
1.Ultrasound finding are 
there cyst with more 
than 1 chamber, 
2.are there cyst with 
solid areas inside them 
3.Is there evidence of 
metastases 
4.Ascites  
5.are there lesions on 
both ovaries  
0-1 findings suggestive of 
malignancy  
Assign 1 point 
2-5 findings suggestive of 
malignancy  
ASSIGN 4 POINT 
Serum Ca-125  
 
Level in U/Ml FORMULA 1 
 
Source: SU10_ALGO_TABLE_DIOGNOSIS –gif 
http://protomeg.ticsnetwork.c 
The morphological features or tumor structure is also taken account in this system. 
Score of more than or equal to 5 is significant and use as a cutoff   
Doppler  pulsatility index of <1 and Resistance index of <0.4 points to  malignancy. There 
is no diagnostic benefit of doppler over sonograpic tumour malignancy index 
alone.(19)(20) 
Some of the new biomarkers which could aid in screening are the use of proteomic 
patterns( which are proteins and protein fragments that circulate in the  blood indicating 
early changes caused by genetic mutation)  to identify cancer using enhance laser 
desorption time of flight (SELDI-TOF) technology.  
There is a suggestion in the literature that total and ionized calcium could help in detection 
of ovarian cancer. Leukocytosis detected preoperatively along with thrombocytosis could 
be of prognostic significance as they are found to be elevated in advance cancer (21) 
 
Biomarkers: Although a vast number of serum markers have been investigated few 
have been validated for clinical use : 
1. CA 125 (cancer antigen 125) sensitivity is 50% for early stage disease, sensitivity is 
more in postmenopausal women . 
2. OVA 1 -5 proteins , CA 124 -11, Beta -2 microglobin, Transferrin, Transthyretin,  
Alfa fetoprotein A1. 
Premenopuasal cut-off:  There is a low probability of malignancy if OVA 1 < 5, high if >5  
Postmenopausal cut-off: There is low probability if OVA1 <4.4, high if >/=4.4.  
Sensitivity is 99% for epithelial ovarian cancer. 
3.HE4 Human epididymis protein 4 produced by WFC2 gene expression – HE4 is 
expressed more in serous and endometrioid cancer , ROMA includes CA125 and HE4.The 
other biomarkers are OVX1, Prostaisin, Osteopontin, cytokeratin Kallikrein, AFP, Inhibin, 
Activin , CA 19.9 for detecting CA 125 negative mucinous ovarian tumor , and VEGF , 
vascular endothelial growth factor  a promoter of angiogenesis ,important in tumor growth 
and metastasis . 
 
 
 
 
 
 
 
 
 
        Source: 
openi.nlm.nih.gov 
 
 
 
 
 
 
 
Figure: 1 Origin of Biomarkers 
 
Genetic Risk for Ovarian Cancer: The highest risk of ovarian cancer is associated 
with family history of cancer ,the   BRCAI(chromosome 17) and BRCA2(chromosome 13) 
cancers occur in women approximately 10 years younger than those with sporadic types 
therefore it has been suggested that screening may be initiated at the age of 35 years or 5 to 
10 years earlier than the sign of first diagnosis of ovarian cancer in the family (22) 
(23)(24)(25). Lynch syndrome or hereditary nonpolyposis colon cancer include multiple 
adenocarcinomas , involves colon,  endometrial and ovarian cancer and other malignancies 
of the gastrointestinal and genitourinary systems (26) , mutations that are associated with 
this syndrome are MSH2/MLH1, PMS, PMS2 .Some of the management protocol in place 
for women at high risk for ovarian cancer of genetic origins are genetic counselling and 
testing for BRCAI and BRCA2 and 6 monthly ultrosonography, and OC Pills usage and 
prophylactic bilateral salpingo-opherectomy and even Hysterectomy(27)(28)(29)The. 
Founder effect certain ethnic group like the Ashkenazi Jews, Icelandic women have 
higher carrier rate of BRCA1 and BRCA2 mutated genes. 
The high risk individuals are now recommended to have ultrasound screening 3 monthly 
from the annual screening they use to follow.  
Symptoms:   Most women have vague and non specific symptoms, in premenopausal 
women with early stage disease,  irregular menses , bowel  and urinary(urgency and 
frequency) symptoms could be the presenting symptoms.. In advance–stage disease, 
patients have symptoms related to the presence of ascites, omental metastases , or bowel 
metastases like abdominal distension, nausea and anorexia and early satiety . In one survey 
of 1,725 patients with ovarian cancer 95% recalled symptoms before diagnosis, including 
89% with stage 1 and 2 disease and 95% with stage 3 and 4 disease , some 70% had GI 
symptoms. Meta analysis of 21 mostly retrospective studies shows that most women had 
pelvic and abdominal symptoms with epithelial ovarian cancer(30)(31). The pattern and 
quality of symptoms appear to differ among patients with cancer in terms of frequency / 
regularity or intensity of the symptoms, one study showed the symptom recurring 20-30 
times versus the 2-3 times per month seen with the primary care patient((31).With the great 
need to detect ovarian cancer early so as to improve survival  a  symptom index(SI) has 
been developed to aid clinicians in evaluating women for early symptoms of epithelial 
ovarian cancer. Further validation studies are needed for this index and it is not yet 
recommended for routine clinical use. 
Signs :  The most important sign is the presence of a pelvic mass on examination. A solid 
irregular fixed mass is highly suggestive of ovarian malignancy .If and upper abdominal 
mass or ascites is present it is almost certain it could be a malignancy. 
Diagnosis:  Ovarian cancer survival rate will improve through early detection of the 
disease, but effective screening method has not been established and to this end research is 
continuing to find out the diagnostic method with high sensitivity , specificity and positive 
predictive value, as benign neoplasm , functional cysts of the ovary should be 
discriminated from a malignant tumor.. 
With research and the results of use of HE4 a tumor marker, repeat study of HE4 as a 
tumor marker shows that ROMA ,RMI and CA 125 have their place but HE4 is a stronger 
predictive marker of malignancy and that the use of computed tomography for diagnosis of 
intraperitoneal spread of the disease will add to the specificity of HE4 as a tumor marker. 
(32) .Serum CA 125 measurement is and established protocol in all gynecology-oncology 
centers, the use of RMI (risk of malignancy index) which combines CA125 value 
,ultrasound features and menopausal state to predict risk of malignancy is established.  The 
sensitivity of CA125  that in 80-85 % of women with advance stage of epithelial cancer it 
is found to be high , and only 50% of the time in early disease it is elevated and it is found 
to be elevated in many benign conditions as uterine myomas,cystadenoma of ovary,and 
pelvic inflammatory diseases the specificity of the test is reduced to 75%,(33).Coming 
back to RMI the ultrasound score in RMI scoring is calculated as follows one point is 
given for the presence of ; multilocularity ,ascites  and the presences of metastasis in the 
abdomen ,a score of 0 which indicate absences of any ultrasound features or a score of 0 to 
1 or,  a score 2 or more will give a U value of 1 or 3 , and the menopausal status 
represented by the letter M is allocated a score of 1 for premenopausal state and 3 for post 
menopause, the   menopause score, CA 125 values at the time of evaluation and the 
ultrasound score were used to complete RMI work analysis. Studies have shown of late 
that HE4 can emerge as a promising tumor marker for the diagnosis of ovarian cancer ,not 
many study have been done to test if  ROMA or RMI  has a better diognostic performance, 
a multicenter study shows that ROMA could be a better system with a  a better predictive 
value as compared to RMI for diagnosis of malignant ovarian cancer (34). 
 
Differential diagnosis: Pelvic inflammatory disease, endometriosis,pedunculated 
uterine myomas . 
Patterns of spread:  1.   Transcoelomic 
                                         2.    Lymphaticc 
                                         3.    Hematogenous  
 
Prognostic factors :  Can be grouped into Pathologic, Biologic and Clinical factors . 
Important prognostic variables among the Pathologic factors are the morphology, 
histologic pattern and architecture and grade of the disease, grade of the lesion is not taken 
as an independent prognostic factor  .Clear cell carcinomas have the worse prognosis 
(35)(36).Clinical factors in addition to stage , the residual disease after primary 
cytoreduction, the volume of ascites , patients age and performance status are all 
independent prognostic variables(37) , intraoperative rupture or spillage does not worsen 
prognosis. For early stage disease poor prognostic variable are tumour grade (38), capsular 
penetration, surface excrescences and malignant ascites and not iotrogenic rupture (39) 
Epithelial carcinoma of the ovaries, fallopian tubes, and peritoneum are clinically similar. 
 
Preoperative evaluation: Preoperative testing include: imaging and other testing for 
metastases, tumor markers for diagnosis and as a baseline for post treatment 
surveillance,and  testing for hereditary cancer syndrome. 
 
Initial surgery for Ovarian Cancer:   Ovarian epithelial malignancies are staged 
according to FIGO system, it is based on surgical findings at surgical exploration, it is 
important to have a thorough staging because subsequent treatment depends on it.FIGO  
staging of ovarian cancer 1988 was used for this study ,the latest FIGO staging 2014 is as 
follows: 
 
 
2014 FIGO ovarian, fallopian tube, and peritoneal cancer staging system and 
corresponding TNM. 
I Tumor confined to ovaries or fallopian tube(s) T1 
IA Tumor limited to one ovary (capsule intact) or fallopian tube, No tumor on ovarian or 
fallopian tube surface No malignant cells in the ascites or peritoneal washings 
T1a 
IB Tumor limited to both ovaries (capsules intact) or fallopian tubes 
No tumor on ovarian or fallopian tube surface 
No malignant cells in the ascites or peritoneal washings 
T1b 
IC Tumor limited to one or both ovaries or fallopian tubes, with any of the following: 
IC1 Surgical spill intraoperatively 
IC2 Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface 
IC3 Malignant cells present in the ascites or peritoneal washings 
T1c 
II Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below 
pelvic brim) or peritoneal cancer (Tp) T2 
IIA Extension and/or implants on the uterus and/or fallopian tubes/and/or ovaries T2a 
IIB Extension to other pelvic intraperitoneal tissues T2b 
III Tumor involves one or both ovaries, or fallopian tubes, or primary peritoneal cancer, 
with cytologically or histologically confirmed spread to the 
peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes T3 
IIIA Metastasis to the retroperitoneal lymph nodes with or without microscopic peritoneal 
involvement beyond the pelvis T1,T2,T3aN1 
IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven) 
IIIA1(i) Metastasis ≤ 10 mm in greatest dimension (note this is tumor dimension and not 
lymph node dimension) T3a/T3aN1 
IIIA1(ii) Metastasis N 10 mm in greatest dimension 
IIIA 2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or 
without positive retroperitoneal lymph nodes T3a/T3aN1 
IIIB Macroscopic peritoneal metastases beyond the pelvic brim ≤ 2 cm in greatest 
dimension, with or without metastasis to the retroperitoneal lymph nodes T3b/T3bN1 
III C Macroscopic peritoneal metastases beyond the pelvic brim N 2 cm in greatest 
dimension, with or without metastases to the retroperitoneal nodes (Note 1) T3c/T3cN1 
IV Distant metastasis excluding peritoneal metastases 
Stage IV A: Pleural effusion with positive cytology 
Stage IV B: Metastases to extra-abdominal organs (including inguinal lymph nodes and 
lymph nodes outside of abdominal cavity) (Note 2) 
Any T, Any N, 
M1 
(Note 1: includes extension of tumor to capsule of liver and spleen without parenchymal 
involvement of either organ) 
(Note 2: Parenchymal metastases are Stage IV B) 
T3c/T3cN1) 
Notes: 1. Includes extension of tumor to capsule of liver and spleen without parenchymal 
involvement of either organ. 
2. Parenchymal metastases are Stage IV B. 
Technigue for surgical staging  
A. Staging procedure includes Mid-line incision on the abdomen. 
B.Collection of ascitic fluid / peritoneal washing (50-100 ml saline instilled and recovered)  
C.Systematic exploration of all the intra-abdomianl surfaces and viscera. 
D.Biopsy of all the suspicious areas or adhesions of the peritoneal surfaces, 
E.Sampling of the diaphragm by biopsy or scraping , 
F.Omentectomy and  
G. Retroperitoneal space exploration . 
Results- Metastases in apparent stage 1 and 11 epithelial ovarian cancer can occur  in as 
many as 3 in 10 patients.  
Early stage ovarian cancer – The primary treatment for early stage 1 Epithelial ovarian 
cancer is surgical –that is total abdominal hysterectomy ,bilateral salpingo-oopherectomy , 
and surgical staging. 
Borderline tumors –the principal treatment is the surgical resection of the primary tumor. 
Fertility Preservation in Early stage ovarian cancer can be advised for stage 1A-1C 
with grade 1 to 2 disease , followed by post treatment surveillance with CA125 level 
determination and routine transvaginal ultrasonography , then ovary and uterus may be 
removed at the completion of child bearing. 
Advanced Stage Ovarian cancer- if the performance status of the patient is good patient 
should undergo an initial exploratory procedure with removal of as much disease as 
possible along with the metastatic disease this procedure is referred to as debulking or 
cytoreductive surger (40) (41)(42). The pre-operative assessment of respectability is 
limited ,CA 125 cut –off of 500 U/mL level  has been suggested as a means of predicting 
the probability of optimal resection . The rationale of cytoreductive surgery is 1. The 
physiologic benefit of tumor excision and 2. The improved tumor perfusion and increased 
growth fraction.both of which increase the likelihood of response to chemotherapy or 
radiation therapy.  Large tumor mass has higher chance of having phenotypically resistant 
clones of cells.  
Cytoreductive surgery include –Incision of the abdomen by vertical midline incision , 
ascitic fluid /  peritoneal washing collection , exploration and biopsies in a systematic 
manner assessing the status of the pelvic pelvic organ ,small and large intestine ,mesentery, 
appendix, stomach, liver gall bladder, spleen , omentum ,both diaphragms dome, entire 
peritoneum, retroperitoneal structure such as kidneys,pancreas, and lymph nodes palpation 
along with palpation of the umbilicus is also for any resectable tumor .  
Retoperitoneum is accessed by dividing the round ligament as laterally as possible and then 
developing the pararectal and paravesical spaces,the pararectal space is developed by sharp 
dissection between the medial leaflet of the broad ligament and the external and internal 
iliac vessels taking care to protect the ureter on the medial leaflet and avoiding dissection 
lateral to internal iliac artery which lie inferior and medial to the external iliac vessels ,the 
paravesical space is created by sharp dissection toward the pelvic floor between the 
superior vesical artery and and the external iliac vessels , the pelvis mass be entered from 
the prevesical space or either paracolic gutter ,A  retroperitoneal approach is best if the 
pelvis appears frozen, this approach allows resection of tumor encroaching on the bladder  
or bowel from lateral aspect beneath the bladder and posterior cul de sac reflection, biopsy 
is taken from all suspicious sites.Pseudomyxoma peritonei can be associated with benign, 
malignant and borderline tumor , Frozen section maybe sent,omentectomy and salpingo-
oopherectomy , lymph node sampling and appendectomy may follow.  
Factors which may limit achievement of optimal cytoreduction maybe technical or 
related to poor performance status. Factors that preclude optimal cytoreduction include 
1.Presence of extraperitoneal or retroperitoneal disease or large tumor bulk  
2. Extensive bowel involvement  
3. Parenchymal liver and lung involvement  
4. Presence of massive ascites  
5. Ability of  patient to tolerate cytoreduction, based on age, performance status, medical 
co-morbidities and preoperative nutritional state.  
Cytoreduction is associated with increased survival.  Splenectomy maybe done if tumor 
nodules extend into the splenic hilum; partial hepatic resection too is an option if a lobe is 
involved, in case of diaphragmatic disease stripping or resection can be done; bowel 
resection could be an important part of cytoreduction; there may be a need to do bladder 
and ureteral resection, placement of a port for intraperitoneal chemotherapy may be done 
simultaneously.  
Optimal cytoreduction maybe considered if there is no residual tumor at the end of the 
surgery (R0) although many would consider residual nodules < 1 cm as adequate. 
Interval cytoreduction. following chemotherapy is an option if primary cytoreduction is 
deemed improbable or if patient is not fit for extensive cytoreductive surgery. 
Laparoscopy. In early stages, it may be done if patients are selected carefully, but many 
surgeons think it is not prudent to do laparoscopic surgery in ovarian cancer . 
Adjuvant treatment: 
Early stage (IA) low risk ovarian cancers do not need further adjuvant treatment.  
Early stage (IA and IB) high-risk ovarian cancers are treated with three cycles of adjuvant 
carboplatin and paclitaxel chemotherapy. 
The current GOG trial includes patients with high risk stage I and II disease and offers 
three cycles of carboplatin and paclitaxel followed by randomizing them either to 
observation  versus 26 weeks of weekly low dose paclitaxel (40mg/m2). High risk stage I 
is defined as stage IA or IB  grade 3, stage IC or clear cell carcinomas.  
Radiation therapy for low stage epithelial ovarian cancer is by intraperitoneal 
radiocolloids or whole abdominal radiotherapy.  
 
 
 
 
 
 
 
 
 
 
 
Table: 4 Chemotherapy drug protocol for Advanced stage ovarian cancer  
Combination chemotherapy for advanced ovarian cancer :Recommended Regimen 
Drugs                             Dose                  Administration (hr)        interval        No.of treatment 
Standard Regimen 
Paclitaxel                     175 mg/m2                    3                     Every 3 weeks          6-8 cycles 
Carboplatin                   AUC =5-6                                         
Paclitaxel                     135 mg/m2                     3                   Every 3 weeks          6-8 cycles 
Alternative drugs
a      
(can be given with platinum) 
Topotecan                    1.0-1.25 mg/m2                                    Daily x 3-5 days  
                                     4.0 mg/m2                                            Every 3 weeks or weekly                                 
Gemcitabine                 800-1,000 mg/m2                                 Every 3 weeks         
Doxorubicin, liposomal 40-50 mg/m2                                       Every 4 weeks   
AUC , area under curve dose by Calvert formula;  
Drugs that can be substituted for paclitaxel if hypersensitivity to that drug occurs.  
Patients who cannot tolerate IV chemotherapy can be given  an oral alkylating agent or oral etoposide. 
 
Consolidation and maintenance of clinical response to first line chemotherapy- the benefit 
of consolidation and maintenance chemotherapy is doubtful, patient and physicians may 
consider prolonged single agent paclitaxel an option, but it should not be considered as 
standard care.  
Administration of chemotherapy and amelioration of toxicity Dose and schedule can be 
adjusted to reduce toxic reaction. 
 
Radiation therapy is an alternative to first line combination therapy for selected patients 
with metastatic disease.  
Hormonal therapy as a first line drug is not practiced but may be used to suppress 
recurrent disease  
Immunotherapy  is on trial. 
Treatment Assesment may be done using tumor markers ,rising level during treatment 
indicate treatment failure,radiologic assessment with Computed tomography or PET scan 
or fluorodeoxyglucose FDG-PET can be done . 
Second look laparotomy is not recommended, but second look laparoscopy could have a 
role. 
Secondary treatment .  Secondary cytoreduction or second line chemotherapy can be 
administered.  
 
 
            
 
 
 
 
 
 
 
 
  Table 5:   Second line chemotherapy in recurrent or persistent Epithelial ovarian cancer 
Drugs used in Platinum and Taxane sensitive Disease  
Response Rate 20-40% 
Cisplatin  
Carboplatin   
Paclitaxel (Taxol) 
Docetaxel (Taxotere) 
Drugs used in Platinum and Taxane resistant and Refractory disease  
Response Rate 10-25% 
Topotecan (Hycamtin) 
Etoposide (oral) (VP-16) 
Liposomal  doxorubicin (Doxil) 
Gemsitabine (Gemsar) 
Hexamethylmelamine (Altretamine) 
 
Platinum sensitive disease Platinum and paclitaxel regimen in patient who have not 
received paclitaxel in their primary chemothereupeutic regimen may provide slight 
advantage . 
Platinum resistant and refractory disease – single agent chemotherapeutic drugs like 
paclitaxel, docetaxel, topotecan , liposomal doxorubicin, gemsitibine , oral etoposide, 
tamoxifen and bevacizamud can be tried  
Hormonal therapy as second line therapy – 15 to20% response rate with tamoxifen is 
seen in well differentiated carcinomas of the ovary, Aromatse inhibitors e.g letrozole, 
anatrozole, and exemestane are also being used. 
Targetted therapies Incorporation of angiogenesis inhibitors (bevacizumab) and other 
VEGF inhibitors for first line treatment is not recommended as of now, but may be used as 
a maintenance therapy. 
Dose intense second line chemotherapy, or  
High dose chemotherapy and Autologous bone marrow transplantation may not show  
significant difference in progression free survival (PFS) or overall survival.  
Whole abdominal radiation may be effective in a small subset of patients, but is 
associated with relatively high morbidity. 
Intestinal obstruction maybe related to mechanical obstruction or to carcinomatous ileus –
parental alimentation may be the best option for this group. 
Genome wide tumor analysis if the molecular tumor profile of each individual patient can 
be maintained ,this will help in selecting molecular targeted treatment just right for the 
patient. (43) 
Survival :   There is a trend toward improved survival for ovarian cancer(44). Survival 
rate for all stages from 1976 to 1978 was 29.8%,, for the interval of 1999 to 2001 the 
survival rate was  49.7% 
The 5 year relative survival rate of ovarian cancer is poor at 40-45%(45). The five year 
survival rate for carefully and properly staged patient with stage 1 disease is as high as 
94%, for stage 11 is 73%, for stage 111 or 1V  28%  (46)                                                       
The survival of patients with borderline tumor is excellent , with stage 1 lesion having a 
98% 15 year survival  (47) . Patients who relapsed within 6 months of completing first line 
chemotherapy are classified as platinum resistant and have a median survival of 6-9 
months and a 10% likelihood of responding to chemotherapy, patients who progress while 
on treatment are classified as platinum refractory disease.  
Non epithelial tumours account for about 10% of all ovarian cancers,in the first two 
decades of life , almost 70% of ovarian tumour are of germ cell origin and 1/3 of these 
are malignant , in contrast to the relatively slow growing EO tumour the Germ cell 
malignancies grow rapidly, The most common type of GCT are dysgerminomas, 
immature teratomas and Endodermal sinus tumour , although 20-25% of all benign and 
malignant ovarian neoplasm are are of germ cell origin only about 3% are malignant,it 
account for 5 % of all ovarian cancer according to western figure where as the 
observation in Asia and Africa shows that 15 % of ovarian cancer are of Germ cell type 
and epithelial ovarian cancer is relatively less. The survival rate for all stages, ages and 
types are as follows:  Table 6.    Survival  of  ovarian cancer. 
Epithelial ovarian cancer Stage  5 year survival 
Stage   I  94 % 
Stage   II 73 % 
Stage   III 28 % 
Stage IV 10 % 
 
Non Epithelial Ovarian 
cancer Histologic type  
Stage   5 years 
survival  
10 years 
survival  
Germ cell tumour 
(Dysgerminoma)  
I A  
Advanced  
95% 
68-83% 
 
Immature Teratoma  
 
I 
All stages 
90-95%  
70-80 % 
 
Yolk sac tumour  All stages 60-70 %  
Granulosa cell tumour  >95 % 90% 
Sertoli Leydig tumour  70-90%  
 Germ cell tumour survival range for all stages of Germ cell tumours ranges from 60-
100%(48)(49) The most effective chemotherapy uses bleomycin, etoposide and cisplatin 
(BEP)(50)(51). Stromal cell tumours include granulosa cell tumours, which are low grade 
malignancies in premenopausal women. They can be treated conservatively and adjunct 
chemotherapy is of unproven value. Fertility sparing surgery for young women with malignant 
germ cell tumor may be done (52).  Metastatic tumours to the ovaries are most frequently from 
the breast and gastrointestinal tract(53). There are limited studies conducted in India to study the 
clinicopathologic pattern and survival pattern among younger women with this malady. The 
overall survival of all age of epithelial ovarian tumor is 40 %(54) 
 
 
                                     METHODS 
This study was approved by the Research Committee and Insitutional Review Board 
(Ethics Committee) of Christian Medical College, Vellore. 
Settings:   This study was conducted in the Department of Obstetrics & Gynecology , 
Christian Medical College Hospital, Vellore. Patients with histologically proven ovarian 
cancer who were treated from 1
st
 January 2008- 31
st
 December 2012 were retrospectively 
recruited for this study. The patients with ovarian cancer who were surgically treated  
during this period were identified through the electronic medical records. The Medical 
Records Department was able to come up with the list of all the patients treated in the 5 
year period by using a computer software which was fed with  a disease code number of 
C65 according to the WHO International Classification of Diseases-10 version 2012 
(volume 3). All the patients fulfilling our inclusion criteria were collected, and those who 
had not come for follow-up were contacted by phone and those without contact telephone 
number were written to and were asked to contact us by phone or letter and were also 
asked to come for review in 2014. Mostly oral consent was obtained to include the patient 
for study, and written consent was taken if they attended clinic. If patient had expired, the 
details of death was obtained from a relative.  The patient’s demographic details, clinical 
presentations, histological features, treatments and survival outcome data were collected 
mainly by reviewing the charts, laboratory and radiological records stored in the electronic 
medical records. When necessary, inpatient and outpatient paper charts maintained in the 
Medical Records Department were studied. Other information pertaining to the study was 
obtained through telephonic interview with patient or relatives after getting their consent. 
Data was analyzed using SPSS software. 
Study Design:   This was a hybrid of a retrospective and prospective design. Survival 
analysis was done for the primary outcomes and a cohort design was used for assessing 
risk factors. 
                  FIGURE :2 Flow chart of patient recruitment 
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 Inclusion Criteria:    Patients with all of the features below were selected. 
1. Patients ≤ 40 years with histologically proven ovarian cancer  
2. Operated in CMC Vellore between January 2008 and December 2012. 
3. Primary ovarian cancers 
 
Exclusion Criteria:   Patients with any of the features below were excluded. 
1. Patients above age 40 years 
2. Those who did not have cancer ovary on final histopathology  
3. Patients who were treated with chemotherapy only and not operated. 
4. Those who were operated elsewhere 
5. Those who had ovarian tumors secondary to cancers from other organs 
 
Primary outcomes :   Survival and recurrence pattern and of women 40 years and 
below with ovarian cancer treated in our institution from January 2008  to December 2012  
1. Death and time to death 
2. Recurrence of cancer and time to recurrence 
Secondary outcomes : 
1. Complications of treatment  
2. Pregnancy   
3. Risk factors for death and recurrence 
 
Sample size:   With 90 % expected survival probability, 95% confidence interval and 
7.5 % precision, the calculated sample was 72. The hazard ratio was calculated based on 
the difference in survival probabilities in the two group, the power of the study was kept at 
80%, with alpha error kept at 5% (2 sided alpha). 
Statistical Analysis:   Descriptive statistics were obtained for all variables. Continuous 
variables which were normally distributed were expressed using mean and standard 
deviation; non-normal continuous variables were expressed using median and range. For 
categorical variables count and percentages were given, and for comparing two categorical 
variables crosstabs with chi-square statistics were obtained. Kaplan-Meir estimation 
method was used to get the estimates of mean survival and recurrence time. Tarone-Ware 
test was applied to check the significance of difference between two groups. Statistical 
analysis was carried out using SPSS version 20. 
 
 
 
 
 
 
                                             
 
  
RESULTS 
115 patients were retrospectively enlisted for our study out of which 93 could 
fulfil our inclusion criteria.  
Table 7.   Year of surgery 
          Year     Number of Patients  
          2008        31 
          2009        28 
           2010        12 
           2011         24  
           2012         20  
  
Table 8.   Place Distribution 
 Number of patients  Percent (%) 
Vellore 22 19.1 
Rest of Tamil Nadu  10 8.7 
Rest of India   75 65.2 
Outside India  7 6.1 
   Majority of our patients were coming from outside Tamil Nadu state. 
  
 Table 9.  Histological Distribution of the study patients  
 
Histiopathological 
pathological classification 
(n=111) 
 
Frequency Percent Notes 
Epithelial                      79/111 71  
 Serous 31   28 2 with sarcomatous 
changes 
 Mucinous 23   21 2intestinal 
Subtypes 
 Endometrioid 11   10  
 Cell Clear  2     1.8  
Not specified 2     1.8  
Non epithelial  32 29  
Germ cell tumours 21   18.9  
Mixed GCT 9   8.1  
Immature teratoma  5   4.5  
Yolk sac  4   3.6  
Dysgerminoma  3 2.7  
Sex cord stromal 7 6.3  
Granulosa 3      2.2  
sertoli-leydic 2      1.8  
Gynanroblastoma  1      0.9  
Androgen secreting tumor 1      0.9  
Others 4 3.6  
Metastatic 2      1.8  
Hemangio-endothelioma   1      0.9  
Granulocytic sarcoma  1      0.9  
Borderline 10 9 4 serous,6mucinous 
Note: Description done on the initial 111 patient with ovarian tumor.  
 
 
 
Looking at the 111 patient with ovarian tumor 79(71.1%) patients had epithelial 
tumour, with the following cell types: serous 31, mucinous 23, endometrioid 11, 
clear cell 2 and adenocarcinoma not   otherwise specified 2. 
 Of the 111 ovarian tumours, 10 were borderline tumors (9 %); 4 of these were  
serous  and 6 were mucinous. There were a total of 7 sex cord stromal tumors 
(6.3%): 3  granulosa cell tumors, 2 sertoli leydig cells, one gynandroblastoma an 
one androgen secreting tumor that was not otherwise specified. There were a total 
of 21 germ cell tumors (18.9%): 9 were mixed germ cell tumors, 5 immature 
teratoma , 4 yolk sac, and 3 dysgerminoma, 
There were two metastatic tumors, and two other tumors namely a granulocytic 
sarcoma and a Hemangioendothelioma. 
The median age of the patients was 32 years with a range of 13 to 40.  
                                 Table 10.    BMI 
 
 
 
 
 
 
 
 
 
BMI FREG Percent 
Under weight 
<18.50 
 
22 
 
25.9 
Norma 
18.5-24.99 
35 41.2 
Obese 
> 30 
 
21 
 
24.7 
Severely obese 
> 40 
 
7 
 
8.2 
Total 85 100.0 
Variable N Mean (S.D) 
BMI 85 22.5(5.4) 
 Perfomance status of a patient has prognostic value as with residual disease after 
surgery and volume of ascites. Of the 93, performance status was documented for 
87 patients, 36 of them had ECOG of 0, 45 with ECOG 1 , 5 with ECOG of 2 and 
I with ECOG 3.   
 
Table 11.   Performance status Distribution  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Performance 
status 
Frequency Percent 
0 36 41.38 
1 45 51.72 
2 5 5.75 
3 1 1.15 
Total 87 100 
Most patients were of parity 2 or less as shown in Table 12. 
Table 12.   Parity of the patients 
 
 
 
 
 
 
 
 
Regarding oral contraceptive use we could get information on only 46 patients out 
of which 9 (19.6%) gave history of its use and 37(80.4%) did not.  
Table 13.   Oral contraceptive use 
 
 
 
 
 
 
Parity Frequency Percent % 
0 31 33.3 
1 27 29.0 
2 27 29.0 
3 5 5.4 
4 2 2.2 
6 1 1.1 
Total 93 100 
Oral  
Contraceptive use 
Frequency Percent 
(%) 
Yes 9 19.6 
No 37 80.0 
Total 46 100 
 Of the presenting symptoms we could get information for 91 of the 93 patients , 
2(2.2%) had dyspepsia as the presenting symptom, 26(28.6%) complained of 
distension of abdomen , majority of the patient 44(47.2% came with complaints of 
pain, 20 had other symptoms like  
To elaborate on the other symptoms , about 10 presented with menstrual 
symptoms ranging from secondary amenorrhea to menorrhagia,in fact one patient 
had polymenorrhea for which oral contraceptive was given for almost a year till 
the diagnosis of ovarian tumor was made. one patient had amenorrhea with 
virilization and another complained of voice change ;deepening of voice with 
hirsutism, there were 8 incidental findings ,3 at the time of caesarean sections, one 
at the time of diagnostic laparoscopy for infertility and one at the time of 
abdominal puerperium sterilization , and two during an early pregnancy scan, 
there were few who presented with feeling of mass in the abdomen,and other 
symptoms like backache, pedal edema,constipation, bleeding from rectum with 
sensation of incomplete evacuation , and urinary symptom of pain during 
micturition and one patient presented with pain in the gluteal region which turned 
out to be a granulosa cell tumor. 
 
 
 
 
                               Table 14. Clinical presentation distribution 
Presentation Frequency Percent 
(%) 
Dyspepsia  2 2.2 
Distension 26 28.6 
Pain 43 47.2 
Other 20 22.0 
Total 91 100 
 
 
                                                Table 15. Tumour markers 
Variables n  Median(min,Max  
CA 125 82 92.2(2,19100) 
hCG 35 1      (0.1,6142) 
AFP 36 6.3   (0.5,496274) 
LDH 35 609  (67.3,17400) 
Serum 
Albumin 
 
63 
Mean (S.D) 
3.97(0.72) 
 
                                                  Table 16. Biomarkers 
CA125 Freq. Percent (%) 
<200 54 65.9 
>200 28 34.1 
Total  82 100.0 
 
hCG Freq. Percent (%) 
<5 21 60.0 
>5 14 40.0 
Total  35 100.0 
 
 
 
 
 
AFP Freq. Percent 
(%) 
<5.5 18 50.0 
>5.5 18 50.0 
Total  36 100.0 
LDH Freq. Percent (%) 
<460 11 31.4 
>460 24 68.6 
Total  35 100.0 
Serum 
Albumin 
Freq. Percent 
(%) 
<3.3 12 19.1 
>3.4 51 80.9 
Total  63 100.0 
 
Serum assay of CA 125 for 82 patients ,HCG for 35,AFP for 36, LDH for 35 , and 
serum Albumin for 63   was done , and of the 93 patients with serum CA125 28 
patients had assay >200 U/Ml,d  of the 35 who had HCG assay 14 had values >5 
and of the 36 patients with serum AFP assay ,18 had values >5.5 and of the 
patient with pre-operative serum Albumin ,of the 63, 12 had serum albumin less 
than 3.3 mg/dl. 
 
Table 17.  Primary treatment distribution: 
Primary 
Treatment 
Frequency Percent 
Surgery 72 77.4 
Chemo 21 22.6 
Total 93 22.6 
 
Surgical staging was done according to FIGO (International Federation of 
Gynecology and Obstetrics) 1988. 47 of the 93 were staged as Early (from stage 
1a to stage 2c ) and 46 patients were staged as advanced stage from stage 3a to 
stage 4)   . 
 
Table 18.   Stage distribution 
Stages Freq. Percent 
Early stage 47 50.5 
Advanced stage 46 49.5 
Total 93 100 
 
  
Table 19.  Complexity of surgery distribution 
Complexity 
  of surgery 
Frequency Percent 
% 
Simple 21 22.6 
Intermediate 69 74.2 
Complex 3 3.2 
Total 93 100 
 
 
Surgery for most patients was of intermediate complexity as sown in Table 19. 
 
Regarding optimal cytoreduction or surgical clearance , 53 of the 93 had no gross 
residual tumor ,15 had less than 1 cm residual (optimal cytoreduction) , 19 had > 
1 cm residual and three had open laparotomy with  biopsy . 
 
Table 20.  Surgical clearance 
Surgical  
Clearance 
 
Frequency 
 
Percent % 
No gross residual  56 60.2 
Less than 1 cm  
Residual 
 
15 
 
16.1 
More than 1 cm 
Residual 
 
19 
 
20.4 
Biopsy only 3 3.2 
Total 93 100 
 
 
 
 
 
Fertility sparing surgery was done in 23 patients (27%). It was found out that 
three of our patients had become pregnant and had given birth. 
Table 21 .    Fertility sparing surgery distribution 
Uterus  Frequency Percent % 
Removed 63 73 
Not 
Removed 
 
23 
 
27 
Total 86 100 
 
Regarding the complication of surgery nobody died intra-operatively nor within 
28 days of surgery of the 115 operated. The commonest complication was post-
operative fever with 21 patients out of 115 having it. Five patients a woun 
problems that included one with burst abdomen. Paralytic ileus was seen in one 
patient, spinal headache in one, ureteric injury in one and underwent uretero-
neocystectomy. One had parastomal abscess and prolapse of the colostomy. 
Relaparatomy was required in one patient with hemoperitoneum : this was a case 
of mucinous adenocarcinoma who underwent total abdominal  hysterectomy with 
bilateral salpingo-oopherectomy with omentectomy and appendectomy.  
 
 
 
Table 22.    Complications of surgery 
COMPLICATION N PERCENT 
Fever 21 19 
Paralytic ileus 1 0.9 
Thromboembolism 0 0 
Others 7 6.3 
 
Majority of our postoperative cases did not have complications. 
 
Table 23.    Tumour Types distribution 
 
  Tumor Frequency Percent %  
Epithelial tumour 64 69.6 
Non-epithelial tumour 28 30.4 
Total 92 100 
 
 
 
 
Table 24.   Histological type distribution 
 
Histology Frequency Percent  
Epithelial 64 68.8 
Sex cord 
Stromal 
4 4.3 
Germ cell 21 22.6 
Other   4 3.2 
Total 93 100 
 
Other includes: 1. Granulocytic sarcoma of ovary 2. Hemangoepithelioma  
 
 
 
 
 
 
 
For secondary treatment of the disease 5 had surgery,23 had chemotherapy, I had 
radiotherapy, 1 (androgen secreting tumor) , and 31 patients did not have 
secondary treatment with us. 
 
Table 25.   Grade of tumour  
Grade Frequency Percent% 
Well 
Differentiated 
 
15 
 
16.1 
Moderate 13 14.0 
Poor 21 22.6 
Not described 44* 47.3 
Total 93 100 
 
*Many serous tumours did not have grading as they are assumed to be high grade 
by its very nature. Sex cord and germ cells tumours are usually not graded .  
 
 
 
 
Table 26.   Secondary treatment distribution  
Secondary 
treatment 
Freq. 
Percent 
(%) 
Surgery 5 8.2 
Chemotherapy 23 37.7 
Radiotherapy 1 1.6 
Other 1 1.6 
None 31 50.8 
Total 61 100 
 
A significant number of our patients could not afford secondary treatment. 
   Table 27.   Recurrence Distribution  
Recurrence Freq. 
Percent 
(%) 
Yes 29 37.7 
No  48 62.3 
Total 77 100 
 
The mean recurrence rate was 38% 
 
 
There were 76 patients on whom survival and progression free time was 
calculated, and out of the 76 patients there were total of 10 deaths during our 
follow period with an estimate mean survival time of 5.4 years with standard error 
of .239 years(95%CI 4.971-5.908).66 (87 %) patients were censored mainly for 
two reasons ,first reason being that quite a number  of our patients(14 of them) 
survival was known up to certain time after the surgery followed by loss of 
contact  , this year 2014 we were sure of 29 patients survival, there were 23 
patients who were lost to follow-up after surgery.   
Table 28.   Survival  distribution  
Survival 
status 
Freq. Percent (%) 
Alive 66 86.8 
Dead 10 13.2 
Total 76 100 
 
 
 
 
Table 29.  Survival and recurrence based on tumor types 
Tumour 
Survival status 
Total 
Recurrence 
Total 
Alive Dead Yes No 
Epithelial tumour 42 9 51 23 29 52 
Non-epithelial 
tumour 
23 1 24 5 19 24 
Total      65 10 75 28 48 76 
 
9 of the patients in epithelial group and 1 in the non epithelial group died during follow up  
 
Table 30.  Survival based on stage of the disease 
 
Stages 
Epithelial tumour Non-epithelial tumour 
Survival status 
Total 
Survival status 
Total 
Alive Dead Alive Dead 
Early stage 23 0 23 15 0 15 
Advanced stage 19 9 28 8 1 9 
Total 42 9 51 23 1 24 
 
 Patient with Early stage disease survival rate was 100%  
Table 31.  Recurrence based on tumor types and stages 
Stages 
Epithelial tumor Non-Epithelial tumor 
Recurrence status 
Total 
Recurrence status 
Total 
Yes No Yes No 
Early stage 0 23 23 3 12 15 
Advanced stage 23 6 29 2 7 9 
Total 23 29 52 5 19 24 
 
 
 
 
Table. 32 Survival and recurrence state based on primary treatment  
Primary 
treatment 
Survival status 
Total 
Recurrence status 
Total 
Alive Dead Yes No 
Surgery 57 3 60 16 44 60 
Chemo 9 7 16 13 4 17 
Total 66 10 76 29 48 77 
 
Survival in the primary chemotherapy treated group was poor, an recurrence was high 
Table 33.  Time to death 
Dead Censored Mean Survival time 
Total 
No. of 
Patients 
No. of 
Events 
Total 
No. of 
Patients 
 % Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
76 10 66 86.8% 5.439 .239 4.971 5.908 
 
Figure 3.  Overall survival 
 
Table 34.  Time to recurrence 
Dead Censored Mean Recurrence time 
Total 
No. of 
Patients 
No. of 
Events 
Total 
No. of 
Patient
s 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
76 28 48 63.2% 4.261 .295 3.682 4.840 
 
 
Figure 4.  Overall Progression Free Survival   
Table  36. Time to Death by histology (Epithelial Vs Non Epithelial tumors) 
  
Tumours 
 
Total 
No of 
Patients 
 
Total 
No of 
Events 
Censored Mean Survival time 
 
 
Sig
a
 
Total 
No of 
Patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Epithelial 51 9 42 82.4% 5.000 .347 4.319 5.681 
 
0.100 
Non 
Epithelial 
24 1 23 95.8% 6.028 .235 5.568 6.489 
Overall 75 10 65 86.7% 5.431 .241 4.958 5.903 
 
As for comparison of survival time for epithelial and non epithelial tumors, we had total 
number of 51 patients in the epithelial group and 24 patients in the non epithelial group with a 
mean survival time of 5 years ( 95 % confidence interval 4.3 to 5.7), and for the non epithelial 
group with  mean survival time of 6 years with 95% confidence interval(5.6 to 6.5); 9 patients 
from the epithelial group have died and one from non epithelial group (this was a case of 
hemangio–endothelioma of the ovary). There was no statistically significant difference in overall 
survival by histology. 
  
 
Figure:5 Overall survival by histology 
 
 
 
 
 
Table 37.  Time to Recurrence by histology  
 
 
Tumours 
 
Total 
No of 
Patients 
 
Total 
No of 
Events 
Censored Mean Recurrence time 
 
 
Sig
a 
Total 
No of 
Patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Epithelial 51 22 29 56.9% 3.799 .378 3.058 4.539 
0.022 
Non 
Epithelial 
24 5 19 79.2% 5.315 .389 4.553 6.078 
Overall 75 27 48 64.0% 4.304 .297 3.722 4.886 
a. Significance is calculated using Tarone-Ware test. 
 
The time to recurrence for epithelial tumors was 3.8 years (95 % CI 3.1 to 4.5) an for 
nonepithelial tumors it was 5.3 years (95 % CI 3.7 to 4.9). This was statistically 
significant (p=0.022).  
  
Figure 5. Progression Free Survival by histology 
 
 
 
 
 
 
 
 Table 38.  Time to Death by primary treatment  (Surgery Vs Chemotherapy) 
Treatment 
Group 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean survival time 
Sig
a 
Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Surgery 60 3 57 95.0% 5.945 .183 5.587 6.302 
<0.001 Chemo 16 7 9 56.3% 3.641 .555 2.554 4.728 
Overall 76 10 66 86.8% 5.439 .239 4.971 5.908 
a. Significance is calculated using Tarone-Ware test.  
 
The mean overall survival time of for primary surgery was 6 years (95 % C.I 5.6 to 6.3) and 
3.6 years (95% CI 2.2 to 4.7) years for chemotherapy. Tis was statistically significant 
(p<0.001).  
 
 Figure 6.  Overall survival by primary treatment 
 
 
 
 
 
 
Table 39. Time to recurrence 
Treatment 
Group 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean Recurrence time 
Sig
a 
Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Surgery 60 16 44 73.3% 4.809 .306 4.209 5.408 
<0.001 Chemo 16 12 4 25.0% 2.246 .517 1.233 3.259 
Overall 76 28 48 63.2% 4.261 .295 3.682 4.840 
a. Significance is calculated using Tarone-Ware test.  
 
The mean time to recurrence after primary surgery was 4.8 years (95 % CI 4.2 to 5.4) and 
for neoajuvant chemotherapy it was 2.3 years (95 % CI 1.2 to 3.3). This was also 
statistically significant (p<0.001). 
 
 Figure 7. Progression free survival by primary treatment 
 
 
 
 
 
Table 40. Time to death by Stage of disease (Early vs Advanced) 
Stages 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean survival time 
Sig
a 
Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Early 
stage 
38 0 38 100.0% 
Can’t be calculated because in early 
stage group every patients were 
censored, i.e no events occurred. 
- Advanced 
stage 
38 10 28 73.7% 
Overall 76 10 66 86.8% 
 
Time to Death by stage of cancer could not be done as all the 38 patients in the early 
stage had all survived up to the follow up time. Of the advanced group, 10 out of the 38 
had died.  
 
 Figure 8. Overall survival by Stage of disease 
 
There is a clear difference in survival curves between early and late stage disease. 
 
 
 
 
 
Table 41. Time to Recurrence by Stage of disease 
Stages 
 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean survival time 
Sig
a 
Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Early 
stage 
38 3 35 92.1% 5.877 .176 5.532 6.221 
<0.001 Advanced 
stage 
38 25 13 34.2% 2.651 .398 1.872 3.430 
Overall 76 28 48 63.2% 4.261 .295 3.682 4.840 
 Figure 9. Progression Free Survival by stage of disease 
There was a statistically significant difference in time to recurrence between 
patients with early stage disease and advanced stage disease (p<0.001). 
 
 
 
 
 
Table: 44 Cytoreduction (Optimal Vs Sub-Optimal) 
Time to death 
Cytoreduction 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean survival time 
Sig
a Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Optimal 
cytoreduction 
59 5 54 91.50% 5.73 0.20 5.34 6.13 
0.003 Sub-optimal 
cytoreduction 
17 5 12 70.60% 3.67 0.72 2.25 5.09 
Overall 76 10 66 86.80% 5.44 0.24 4.97 5.91 
a. Significance is calculated using Tarone-Ware test. 
 
Figure:11 
P-Value= 0.003 
  
Table: 45 Time to recurrence 
Cytoreduction 
Total 
No of 
patients 
Total 
No of 
Events 
Censored Mean survival time 
Sig
a Total 
No of 
patients 
Percent 
(%) 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Optimal 
cytoreduction 
59 18 41 69.50% 4.66 0.30 4.07 5.25 
0.002 Sub-optimal 
cytoreduction 
17 10 7 41.20% 2.43 0.64 1.18 3.68 
Overall 76 28 48 63.20% 4.26 0.30 3.68 4.84 
a. Significance is calculated using Tarone-Ware test. 
 
 
Figure: Tables: 46  
 
 
 
 
 
 
 
 
 
 
 
P-Value= 0.002 
Table 42: Univariate and multivariate Cox regression analyses of potential risk factors 
affecting survival of ovarian cancer patients after surgery 
Factors N 
Survival 
status 
Unadjusted (Univariate) Adjusted (Multivariate) 
Dead 
(n) 
Alive 
(n) 
HR (95% C.I) P-value HR (95% C.I) P-value 
Histology 
 
Non-Epithelial 
Tumour 
Epithelial 
tumour 
 
 
24 
 
51 
 
 
1 
 
9 
 
 
23 
 
42 
 
 
1 
 
5.81 (0.73-46.22) 
 
 
0.10 
 
 
1 
 
2.22 (0.23-21.34) 
 
 
 
0.49 
Treatment 
 
Surgery 
 
Chemotherapy 
 
 
60 
 
16 
 
 
3 
 
7 
 
 
57 
 
9 
 
 
1 
 
10.17 (2.62-39.4) 
 
 
<0.001 
 
 
1 
 
2.42 (0.54-10.64) 
 
 
0.25 
 
Only type of primary treatment was significant for overall survival. Those who had primary 
chemotherapy were 10 times more likely to die as compared to those who had primary surgery. 
 
 
Table 43: Univaritate and Multivariate Cox Regression analyses of potential 
risk factors for recurrence of ovarian cancer after surgery 
Variables N 
Recurrence 
status 
Unadjusted (Univariate) Adjusted (Multivariate) 
Yes (n) 
No 
(n) 
HR (95% C.I) P-value HR (95% C.I) 
P-
value 
Histology 
Non-Epithelial  
 
Epithelial  
 
24 
 
52 
 
5 
 
23 
 
19 
 
29 
 
1 
 
2.7  (1.02-7.30) 
 
0.05 
 
1 
 
2.36 (0.74-7.51) 
 
0.15 
Treatment 
Surgery 
 
Chemotherapy 
 
60 
 
17 
 
16 
 
13 
 
44 
 
4 
 
1 
 
4.3  (2.01-9.31) 
 
<0.001 
 
1 
 
1.44 (0.60-3.48) 
 
0.42 
Stages 
Early stage 
 
Advance stage 
 
38 
 
39 
 
3 
 
26 
 
35 
 
13 
 
1 
 
14.1 (4.21-47.4) 
 
<0.001 
 
 
1 
 
12.6(3.49-45.49) 
 
<0.001 
 Epithelial histology, primary chemotherapy and advance stage at presentation 
were significant adverse factors on univariate analysis. In multivariate analysis 
the only independent risk factor for recurrence was stage of disease.The hazard 
ratio for recurrence in advanced stages was 12.6(95% CI3.5 to45.5 p<0.001) 
                                                                               
DISCUSSION 
 
Cancer of the ovary is the most fatal of all female gynecological cancers. Worldwide, it is 
the 7th most common cause of death in the female. In India, it is the third most common 
cancer affecting women, next to cancer of the breast and cervix. Although most of the 
literature combines clinical features and treatment of epithelial and non-epithelial tumors, 
these need to be studied separately. It is also not clear how often epithelial tumors effect 
young women and whether the bi-modal age distribution clearly separates out epithelial 
and non epithelial tumors, hence the aim and objective of this study was to evaluate the 
clinico-pathological features and survival outcome of women 40 years and younger with 
ovarian cancer treated at a tertiary care hospital in India. 
Most of the studies from India on ovarian cancer are case reports or clinicopathological 
studies. There are no survival studies done in the below 40 year age group, especially for 
epithelial ovarian cancer.  
 
In our study we were able to follow up 76 patients out of 93 (82 %). In spite of trying to 
contact patients and their relatives by letters, phone calls and email, 18 % of patients were 
lost to follow up. This is a common problem in our country where patients default due to 
ignorance and poverty. Access to cancer care is limited and often patients have to travel 
long distances. Cancer hospitals are also ill equipped to contact patients who default or 
arrange financial help for the poor. 
  Time to death and time to recurrence could be calculated in the 76 patients.  There were a 
total of 10 deaths during our follow period with an estimated mean survival time of 5.4 
years  with a 95% confidence interval of 4.97 to 5.91. There were no peri-operative deaths. 
Of the 28 cases who had recurrence of disease 10 went on to die. All those who died had 
stage III or IV disease; 5 had serous adenocarcinoma (grade 2 or 3), 2 had endometrioid 
type , 1 with mucinous, and one with non specified adenocarcinoma. The only death from 
the non-epithelial group was a rare type of ovarian cancer, a hemangi-endothelioma. We 
could not show a significant difference in time to death between epithelial and non-
epithelial tumours as the numbers wee small. The mean time to recurrence was 4.3 years 
(95% confidence interval 3.68 to 4.84). There was a statistically significant difference 
(p=0.022) in time to recurrence between epithelial (3.8 years) and non-epithelial tumours 
(5.3 years). 
In our study, epithelail cancers were seen in 69%. The commonest histological type was 
serous cystadenocarcinoma(28%). Germ cell tumours constituted 23 % of cases.  
In an Indian study done  (16)  a study to look at the histologic pattern, bilaterality and 
clinical evaluation of 957 ovarian neoplasm done over a period of 10 years in eastern India, 
in all age group, the most common histological type was serous cystadenoma (30%), 
followed by mature teratoma (16%) and mucinous cystadenoma (11%). As in our study, 
epithelial tumors formed 61% of their cases. Serous cystadenoma too was the most 
common malignant tumor. Most of their malignant tumors presented as stage III (60%). In 
the young women in our study, the commonest presentation was pain and 50 % were stage 
I or II. In the study from east India, the overall survival rate was 85% for stage I tumor, 
65% for stage II, 30 % for stage III, and 15.5 % for stage IV tumor. In our study, survival 
of the early stage cancer (stage I and II) showed 100% survival rate .whereas for advanced 
stage (Stage III and IV), the survival rate was 74% with overall survival rate of 87%. 
A Chinese study on young women showed the commonest histologic type to be serous 
adenocarcinoma (56%).  For stage IA disease, their 2 and 5 year survival was 86% and 
82%.(55). They concluded their study by stating that women under 35 years with epithelial 
ovarian cancer mostly have serous adenocarcinoma with a good prognosis so such women 
could have fertlility preserving surgery. 
Another study done in Japan (56) showed that mucinous ovarian cancer was the 
commonest tumor in young reproductive women . 
A large study done over a period of 25 years showed that young age, good performance 
status, early stage, optimal cytoreduction  and lower grade tumors were positive prognostic 
factors for survival (57). Another study on the effect of platinum based chemotherapy on 
survival, the 29 (out of 624) who were below 40 years showed a 5 year survival of 65% 
against the 20% among those above 70 years (13). There are several studies on survival 
among patients with malignant ovarian tumor (15) and all the results showed good survival 
outcome among those who were adequately treated by surgery and chemotherapy..    
In our study, mean survival time of 6 years for surgery (95 % CI 5.6 to 6.3) and mean 
survival time of 3.6 years for chemotherapy (95 % CI 2.6 to 4.7). Although this was 
statistically significant, it may be that primary surgery was done mainly for early stage 
disease and neoadjuvant chemotherapy was done for the advanced cases. 
 
There was a statistically significant difference in time to recurrence between early and late 
stages. There were only three recurrences in the early stages, with mean survival time of 
5.9 years  and 25 recurrence in the advanced stages with  mean survival time of 2.7 years 
(p value  <0.001) . 
 
The survival rate was 91.50% for optimally reduced with mean survival time of 5.7 
(95%C.I 5.34 to 6.13) and survival rate of 70.6 % for suboptimal cytoreduction with mean 
survival time of 3.7 years (95%C.I 2.25 to 5.09). This was statistically significant ( p value  
0.003). The time to recurrence for the optimal and suboptimal group showed progression 
free survival rate of 70% and 41% with given mean survival time of 4.66 and 2.43 years     
(p value 0.002). Most studies have shown that optimal cytoreduction is the most important 
prognostic variable, at least the one variable that something can be done about. In recent 
years the definition of optimal cytoreduction has moved from less than 2 cm residual to 1 
cm and currently to zero residual. 
 
There are a number of Indian studies on germ cell tumors as well as sex cord stromal cell 
tumors. One study done over a period of 11 years recruited 23 patients with a median age 
of 19 years. The study wanted to find out if neoajuvant chemotherapy followed by interval 
debulking would help those with bulky tumor (7). Neadjuvant chemotherapy followed by 
fertility sparing surgery could be a reasonable option for malignant GCT not suitable for 
optimal cytoreduction surgery (58). Another Indian series on 28 cases of Immature ovarian 
teratoma done in a group with median age of 19 years(59), most common presentation was 
pain abdomen. Neuroepithelium was seen in 26 cases of which 6 had grade1, 13 had grade 
2, and 7 had grade 3. (59). There were 7 deaths during a median follow up of 33 months. 
Another study which tries to find out if there could be a role for aggressive cytoreduction 
surgery for non-dysgerminoma mature tumor, in these study with 33 patients with germ 
cell tumor ,12 had EST ,11Dysgerminoma,7 with Mixed GCT, and 3 with Immature Germ 
cell tumor, this study indicate that there could be a role for aggressive cytoreduction. In 
another study on 27 patients with pure dysgerminoma of the ovary done in Mumbai (60), 2 
of 10 patients in stage I patients underwent unilateral salpingo-oophrectomy ,with no 
further adjuvant chemotherapy; the  rest underwent total abdominal hysterectomy with 
bilateral salpino-opherectomy (TAH / BSO) followed by adjuvant chemotherapy; Patients 
in stage II and stage III had total abdominal hysterectomy followed by postoperative 
radiotherapy . One patient presented in stage 1V and three patients with recurrence after a 
full treatment in another center. The disease free as well as overall survival at 108 months 
for the 24 cases primarily treated at Mumbai was 81% and 88%, and for patients in stages I 
and II 100% (Kaplan-Meier estimation). The study stressed the need for controlled clinical 
trials to devise optimal therapy in early clinical stages and use of chemotherapy for 
advanced disease, for this highly curable disease. 
 
A study was done to see outcomes of malignant ovarian germ cell tumors treated in Chiang 
Mai University Hospital over a nine year period.(15)  This was a clinico-pathological and 
survival study. Of the 72 cases recruited, the mean age was 21.6 years and 11.8% were pre-
menarchal. The two most common symptoms were pelvic mass and pelvic pain. Two-
thirds of the studied patients presented at an early stage. The common histology in 
descending order of frequency were 1. immature teratoma (34.2%) 2. endodermal sinus 
tumor (28.9%),3. dysgerminoma (25%),4. mixed type (10.5%) and 5.choriocarcinoma 
(1.3%). Treatment with fertility sparing operations and adjuvant chemotherapy with a BEP 
regimen showed a good outcome. An advanced stage was found to be  a risk factor for 
recurrence.  
Of the 9 mixed germ cell tumors seen in our series, 5 were stage III or IV,and four were 
stage I or II. Of the immature type, 3 were stage III and 2 were stage 1a; of the four yolk 
sac tumors, 1 was stage 1V and 3 were stage 1a to 1c, and of the dysgerminomas, 1 was 
stage Ia, another Ic and the third IIa. The survival rate for early stage was 100% and 
advanced stage was 74% with overall survival of 87%.  
 
A  study on Granulosa cell tumor done over a 10 year period showed(61) the good 
prognostic factor for this tumor was optimal cytoreduction(p 0.02). Presence of nuclear 
atypia(p<0.001), increased mitosis(0.03) were the other factors that impacted survival 
significantly. Age, stage of the tumor, parity and size of the tumor had no significant effect 
on survival. Patients who had chemotherapy had median survival of 60 versus 48 than 
those who did not have, but it was not statistically significant (p value 0.08)   
 A Chinese study on 46 patients with granulosa cell tumor over a period of 10 years 
showed that FIGO stage (p value of 0.00030), presence of nuclear atypia (p value 0.036) 
and, increased mitosis (p value 0.0020 were three factors that impacted survival(62).  
 
Regarding grade of the tumor, of the 93 patients in our study, 15(16.1%) had well 
differentiated type, 13(13.9%) were moderately differentiated and, 21(22.5%) poorly 
differentiated.   
 Perfomance status of a patient has prognostic value as with residual disease after surgery 
and volume of ascites. Of the 93, performance status was documented for 87 patients, 36 of 
them had ECOG of 0, 45 with ECOG 1 , 5 with ECOG of 2 and I with ECOG 3.   
 
53 of the 93 had no gross residual tumor, 15 had less than 1 cm residual (optimal 
cytoreduction) , 19 had > 1 cm residual and three had open laparotomy with  biopsy . 
For secondary treatment of the disease 5 had surgery, 23 had chemotherapy, I had 
radiotherapy, 1 (androgen secreting tumor), and 31 patients did not have secondary 
treatment with us.  
Surgical staging was done according to FIGO (International federation of Gynecology and 
Obstetrics )1988.47  of the 93 were staged as Early (from stage 1a to stage 2c ) and 46 
patients were staged as advanced stage from Stage 3a to stage 4)   . 
23 of our patients had fertility sparing surgery, it was found out that three of our patients 
had become pregnant and had given birth.  
Early stage disease and non epithelial histology had the best prognosis in multivariate 
analysis. 
 
 
  
Cox proportional hazard model are used to determine the endpoint effect of variables like 
histology,primary treatment ,surgery vrs chemotherapy and residual disease on 
survival,early stage disease and non epithelial histology had the best prognosis in 
multivariate analysis. 
The important reasons for poor patient compliance and follow up to the primary 
treatment are financial constraints. Surgery and chemotherapy are beyond the 
means of almost a third of our population. Most patients do not have insurance. 
The other reason for poor follow up to cancer care is lack of knowledge. The 
patient and family are not aware of the importance of follow-up and the 
possibility of recurrence. Poor communication by health professionals and a lack 
of health infrastructure compound the problem. . In our country illiteracy and 
poverty play a role for the above limitations.  
 
 
 
 
 
 
  
 
 
LIMITATIONS and STRENGTHS 
 
Limitations :    This study analysed available data of all the patients who 
underwent surgery for ovarian tumor in our hospital during a 5 year period from 
2008 to 2012. The major limitation of our study is that 18 % of patients who are 
completely lost to follow-up after surgery. Information on the others was also 
gained in the main part by phone calls and letters. It was a big challenge to 
contact our patients as telephone numbers were often not provided. Also 
telephone and postal numbers provided to the hospital were incorrect or had not 
been updated. There could be a bias in the follow up in that there could have been 
more complications, recurrences and deaths in the 27 women who were 
completely lost to follow up. Since this was mainly a retrospective analysis, 
collection of information could have been incomplete with a differential bias 
Another limitation was the small number of events. Only 10 deaths had been 
identified in the 76 patients that were followed up. This made risk factor analysis 
difficult. Statistical assumptions could have been violated in the multivariate 
analysis. 
  
Strengths :   This study is one of the first to look at ovarian cancers in young 
women. At the Christian Medical College Hospital, medical records, laboratory 
data and radiological reports are stored electronically hence access and retrieval to 
patient information is relatively easy. In the past few years more and more 
patients and their family members have mobile phones and can be contacted. 
Another strength of this study was the good statistical analysis as the institution 
has a well established department of biostatistics. Survival analysis could be done 
stratified  for the important variables such as  stage of disease, primary treatment 
and histological type of cancer. 
 
Suggestions for improved care :   In order to improve our comprehensive 
cancer treatment services, capacity building of all the professionals responsible 
for patient care as well as documenting and storing medical records of the patients 
is essential. There has been a push for a Cancer Registry for the country. 
Standardizing our diagnostic methods and our treatments so that these can be 
audited for quality improvement is to be encouraged. All the professionals 
concerned should follow a minimum standard of reporting and documentation. 
Electronic entry of all information about the patient, contact address, email and 
phone numbers would make follow up and ascertainment of disease status easier. 
The employment of social workers to contact defaulters and referral to 
professionals nearer the patient’s home would ensure that compliance to treatment 
is enhanced. 
 
  
 
CONCLUSIONS 
 
(1) Even in women 40 years and less, 70 % of the ovarian tumors were epithelial in 
histological type. Serous ovarian cancer was the most common.  
 
(2) Germ cell tumor constituted 20 % of the ovarian cancers. Mixed malignant germ 
cell tumor was the commonest type. 
 
                 (3)  The mean overall survival was 5.4 years. The overall survival was  87%. 
For epithelial tumors it was 82 % and for non-epithelial tumors it was 96 %.   
For early stage disease it was 100 % but for advanced stages it was 73 %. 
 
(4) Disease recurrence was seen in 37 %. The mean overall progression free time was 
4.3 years. For epithelial tumors it was 3.8 years and for non-epithelial tumors it 
was 5.3 years. For early stage disease it was 5.9 years and for advance stages it 
was 2.7 years.  
 
(5) Early stage disease and non-epithelial histology had the best prognosis in 
            multivariate analysis. 
  
 
 
 
 
IMPLICATIONS 
 
This study has reiterated that early diagnosis, aggressive surgical debulking and 
compliance to chemotherapy are the most important factors that determine 
outcome in young women with ovarian cancer. Treatment of such cancers should 
be done in specialized cancer centers or gynecological oncology units of tertiary 
level hospitals. 
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                                                     ANNEXURES  
ANNEXURE I          ABBREVIATIONS 
AFP                                  Alpha fetoprotein 
BMI                                 Body Mass Index 
ECOG                              Eastern Cooperative Oncology Group 
EOC                                 Epithelial ovarian cancer 
FIGO                                International Federation of Obstetrics and Gynecology 
GCT                                 Germ cell tumor  
H CG                               Human Chorionic Gonadotropin   
ICMR                              Indian Council of Medical Research 
LDH                                Lactate Dehydrogenase 
PFS                                 Progression free survival  
SPSS                               Statistical packages for social sciences  
TNM                              Tumor node and metastasis  
 
                                
 
ANNEXURE II 
INFORMED CONSENT 
Participant Information Sheet 
Christian Medical College, Vellore. 
Department of Obstetrics and Gynaecology  
Study on Follow –up of women under 40 years with ovarian cancer 
You are being requested to participate in a study to see how women under 40 years present   
with cancer ovary , what  treatment was given and how did  they respond to the treatment , 
we hope to include about 70 women in the study.  
What is the need for the study. – Cancer of the ovary is one of the commonest cancer in
  women, therefore we are starting this study so as to gain further knowledge about 
this disease in young women.    
Is there a harm to you in participating in this study   
No harm will be done, as your privacy and confidentiality will be respected. 
If you take part I what will you have to do 
 It is to permit us to review your medical records and few questions regarding your state of 
health will be asked of you. 
Can you withdraw from this study after it starts  your participation in this study is 
entirely voluntary and you are also free to decide to withdraw permission to study in this 
study ,if you do so this will not affect  your usual treatment in this hospital in any way.  
 Will you  have to pay for this study No payment is required for this study ,any other 
treatment that you usually take will continue and the routine charges for the treatment will 
be paid by you.  
Will your personal detail be kept confidential? The results of this study will be 
published in a medical journal but you will not be identified by name in any publication or 
presentation of the results, however your medical notes may be reviewed by people 
associated with the study without your additional permission if you are included in this 
study.  
If you have any further questions please ask Dr. Eileen Lalrinpuii (918056755392), 
Dr.Abraham Peedicayil:  or email to og1@cmcvellore.ac.in  
 Format for Informed Consent Form for Subjects 
Informed Consent form to participate in a research study  
 
Study Title: Out Come of Women 40 Years and below with Cancer ovary 
Study Number: ________________ 
Subject’s Initials:____________ Subject’s Name: _______________________ 
Date of Birth / Age: ___________________________ 
 
(Subject) 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current study 
and any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
 (v)  I agree to take part in the above study. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________           
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
 
 





Page 1 of 5
sno hospino contno age ht wt par tl ocp dur perfsta pres
famhi
stbr
famhi
stco
famhi
stut
famhis
tov
histo
lo
preo
p
preop
fb
preopc
a12 afp ldh hcg
n0t
hr salb
primr
x
surg
clr
adne
xa
uteru
s
splen
ec
bowelre
sno
pelvicl
nto
noposn
ode
para
ln
totpa
ra
oment
ect
appendi
sec
diaphst
rip
histo
l grad
stag
e
firstche
mo id
secon
rx
comp
lsx
compli
csx preg
recu
r recurdate
deat
h datodeath
1 106052D 9486173860 40 153 71 0 2 1 2 2 2 2 2 1 1 1 2770 4.2 2 3 2 1 2 2 2 11 9 2 2 1 3 2 1 21/12/2009 1 09/12/2011
2 471233A 34 1 1 2 1 1 2 145 2 2 2 2 1 2 2 0 0 2 0 1 2 2 1 8 9 1 1 2 2
3 219261D 9437249634 22 156 75 1 2 0 3 2 2 2 2 3 2 1250 422 7.46 1 3 2 1 2 2 0 0 2 0 1 2 2 11 3 9 5 2 6 2 2 2 2 04/08/2014
4 240933D 8.80182E+12 22 52 1 2 2 1 4 2 2 2 2 1 2 8.2 4.4 1 2 1 1 2 2 2 2 2 2 1 2 2 2 1 1 2 6 1 2 2 2 07/08/2014
5 942295C 36 0 2 3 2 2 2 2 1 26.5 1 2 1 2 1 2 2
6 192739D 9734772915 30 157 53 1 2 1 96 3 2 2 2 2 1 2 2 13.7 4.9 2 1 1 1 2 1 2 2 2 1 2 2 1 2 2 2 2 04/08/2014
7 040181D 36 155 60 2 2 1 9 1 4 2 2 2 2 2 5.53 1 1 1 2 1 2 2 0 0 2 0 1 2 2 9 5 1 6 2 6 2 4 2 2 2 27/12/2013
8 363954D 9895396873 27 149 45 1 2 2 2 2 2 2 3 7 1740 72.1 2.9 1 1 1 2 2 2 10 0 2 0 1 2 2 11 1 7 9 2 6 1 1 2 2 08/08/2014
9 276135D 9333438595 40 144 40 2 1 1 2 2 2 2 2 1 1 2 4620 4.8 2 1 2 1 2 2 0 0 2 0 1 2 2 1 2 9 2 1
10 318102D 9835117977 33 153 64 1 2 2 2 2 2 2 2 1 1 2 661 2 2.8 2 3 2 1 2 2 0 0 2 0 1 1 2 3 2 7 2 2 2 2 1 2 1 07/04/2011 1 20/03/2012
11 406832D 9443956693 21 144 65 0 2 2 2 3 2 2 2 2 3 2 15.8 1.22 2730 286 2 1 1 1 2 2 2 1 0 2 0 1 2 2 6 5 3 5 2 6 2 4 1 2 2 23/08/2014
12 424459D 33 58 2 2 3 2 2 2 2 1 10.6 1 1 1 2 1 2 2 0 0 2 0 1 1 2 2 1 1 2 6 2 4 2
13 472173d 9885257468 26 2 1 2 3 2 2 2 2 3 2 20.4 1.34 6804 122 2 1 1 1 2 2 2 1 0 2 0 1 2 2 11 5 3 5 2 6 2 1 2 2 2 06/08/2014
14 476103d 9732511620 34 144 33 0 2 2 2 1 2 2 2 2 2 1 1 2 827 30 1 2.6 1 1 1 2 2 2 7 4 2 0 1 2 2 2 5 10 2 4
15 512728d 9732981850 18 157 57 0 2 2 0 3 2 2 2 2 1 2 1 1 1 1 2 2 2 0 0 2 0 2 2 2 11 5 10 9 2 2 1 2 1 20/07/2009 1 10/01/2010
16 519833d 9894293869 32 155 46.6 3 1 2 0 3 2 2 2 2 1 2 2 1 1 2 1 2 2 0 0 2 0 1 2 2 2 9 2 2 6 2 4 2 1 04/03/2011 1 27/03/2011
17 567463d 9847513212 37 157 40 1 2 1 3 2 2 2 2 1 1 84.4 1 3.5 2 1 2 1 2 1 0 0 2 0 1 2 2 11 3 9 2 1 6 3 2 2 2 20/03/2014
18 579099d 9491641779 36 143 37 3 1 2 4 2 2 2 2 5 1 1 1 1 2 1 1 2 0 0 2 0 1 2 2 11 5 5
19 594798d 4182460871 30 159 56.6 2 4 2 2 2 2 1 2 2 1 1 2 1 2 2 0 0 2 0 1 2 2 1 4 1 2 6 1 2 2 2 28/08/2014
20 638777d 23 142 45 0 2 2 0 3 2 2 2 2 1 29 24500 1 2 1 3 3 2 2 2 0 0 2 0 1 1 2 11 5 9 5 2 6 2 1 2 01/03/2012
21 071177d 9943060895 37 164 43 2 1 1 3 2 2 2 2 1 3.4 2 2 2 1 2 2 0 0 2 0 1 2 2 1 3 10 2 2 2 1 01/11/2011
22 779072d 9832089878 36 154 38.2 0 2 2 2 3 2 2 2 2 54.68 2 4 1 1 2 1 2 2 0 0 2 0 1 2 2 11 2 3
23 795351d 35 2 2 0 4 2 2 2 2 2 5.14 1 3.5 1 1 2 1 2 2 0 0 2 0 1 2 2 9 5 3 4
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24 795758d 28 145 35 1 2 1 3 2 2 2 1 1 2 136 4.5 1 1 1 1 2 2 0 0 2 0 1 2 2 1 5 3 2 2 2 2 2 14/09/2012
25 822046d 9088474258 28 146 40.4 0 2 2 0 2 2 2 2 2 1 2 100 0.98 379 0.152 1 4.2 1 1 2 1 2 2 0 0 2 0 1 2 2 1 5 2 2 2 6 3 3 2 2 2 03/09/2014
26 823989d 7872633824 40 156 38.8 2 2 1 1 3 2 2 2 2 1 1 2 2360 1 3.7 1 1 2 1 2 2 0 0 2 0 1 2 2 11 1 1 2 2 6 2 1 2 2 2 08/01/2014
27 859958d 8682960073 21 147 40.9 0 2 1 2 2 2 2 2 61.9 642 455 0.373 4.1 1 1 1 2 2 2 3 0 2 0 1 2 2 11 1 1 2 6 2 4 1 2 2 17/08/2014
28 914506d 1710833642 39 177 65 2 2 2 2 3 2 2 2 2 1 1 4 1 4 3 2 2 2 0 0 2 0 2 2 2 11 5 10 9 2 6 1 2 1 01/03/2011 1 24/05/2011
29 359769c 31 154 60 0 2 2 0 3 2 2 2 2 2 26.6 2 1 1 1 1 2 2 0 0 2 0 1 1 2 1 2 3 2 2 6 2 1 2 2 2 18/06/2014
30 973216d 9933709472 40 158 52.6 3 2 0 4 2 2 2 2 1 10.5 3 1 1 2 1 2 2 0 0 2 0 1 1 2 2 1 1 2 6 2 4 2 2 22/07/2013
31 923183d 94349860721 34 159 74 1 2 1 192 1 3 2 2 2 2 2 7.09 2 1 1 1 1 2 2 0 0 2 0 1 1 2 2 1 3 2 2 6 2 1 2 2 2 04/08/2014
32 941050d 32 149 40.36 0 2 2 1 3 2 2 2 2 1 1 248 850 892 0.8 2 3 1 3 2 1 2 2 0 0 2 1 2 2 11 3 8
33 892253d 9171544637 28 156 48.1 0 2 2 0 4 2 2 2 2 1 2 15 1 4.8 2 1 1 1 2 2 0 0 2 0 1 2 2 11 3 9 2 1 2 2 4 2 1 24/05/2012
34 595385d 9446184930 33 165 72 2 2 2 4 2 2 2 2 4 33.2 4.3 1 3 2 1 2 2 0 0 2 0 2 2 2 11 5 9 9 2 1 1 1 2 1 04/09/2013 2 08/09/2014
35 963354d 909233799 23 145 39.2 0 2 2 1 2 2 2 2 2 1 1 485 84.6 511 0.1 2 4 1 1 1 2 2 2 0 0 2 0 1 2 2 11 3 9 2 1 2 2 1 19/07/2013 2 17/08/2014
36 951621d 9430104504 31 158 62.8 2 2 0 4 2 2 2 2 7.3 0.64 1 1 5 1 1 1 2 2 2 0 0 2 0 2 2 2 9 2 1 2 1 2 2 2 24/08/2014
37 755895b 36 160 65.5 1 2 1 3 2 2 2 2 3 2 122 1.33 380 2 2 1 1 1 2 2 0 0 2 0 1 2 2 11 3 1 5 1 6 2 2 2 24/02/2014
38 970454d 9895039750 40 150 70.5 1 2 2 1 3 2 2 2 2 1 2 1 1 1 2 1 2 1 2 0 2 0 1 2 2 2 1 9 2 1 2 3 4 2 1 09/08/2011 2 28/08/2014
39 989904d 32 154 82.58 2 2 1 2 2 2 2 2 1 1 2 428 1.64 1 2.9 1 1 2 1 2 2 0 0 2 0 1 1 2 2 1 10 1 2 2
40 012317f 9681194893 29 153 49.6 0 2 0 3 2 2 2 2 1 27.7 2 1 1 1 2 2 2 0 0 2 0 1 2 2 1 1 1 2 6 2 4 2 2 13/05/2013
41 024261d 34 163 34 2 2 2 0 4 2 2 1 2 2 52.6 1 1 1 2 1 2 1 2 1 1 3
42 024823f 9781856399 31 147 54.8 0 2 0 1 2 2 2 2 1 1 150.8 2 1 1 1 2 2 2 1 0 1 0 1 1 2 3 1 3 2 2 6 2 4 2 2 2 04/08/2014
43 020157f 9973848121 18 154 41.4 0 2 2 1 3 2 2 2 2 1 1 491 0.63 409 2 1 1 2 1 2 2 0 0 2 0 1 2 2 1 1 7 2 2 6 2 1 2 2 2 23/08/2014
44 017813f 40 150 58 2 1 1 3 2 2 2 2 2 2 896 4.4 1 3 2 1 2 1 0 0 2 0 1 2 2 1 5 8 2 2 2 2 4 2 1 27/08/2012
45 972680d 8972142036 37 161 52.2 2 1 1 2 2 2 2 2 1 1 19100 1 3.6 2 1 2 1 2 2 0 0 2 0 1 2 2 11 3 10 2 1 3 2 1 2 1 13/06/2012 1 12/10/2013
46 056559f 32 168 71.6 0 2 2 1 3 2 2 2 2 2740 2 1 1 2 1 2 2 0 0 2 0 1 1 2 1 2 5 9 2 6 2 1 2 2 2 18/08/2014
47 057844f 9832011179 26 150 36.06 1 2 0 3 2 2 2 2 1 2 70.1 1.51 20.1 2 1 1 2 1 2 2 9 0 2 0 1 2 2 2 9 2 2 2 2 2 1 12/02/2012
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48 076668f 9035089835 19 155 46.2 0 2 2 1 3 2 2 2 2 0.95 672 0.1 1 1 1 2 2 0 2 1 2 2 11 2 2 24/08/2014
49 075600f 9973661455 34 146 49.7 1 2 0 3 2 2 2 1 2 77.4 1 4.7 1 2 2 1 2 2 0 0 2 0 1 2 2 1 5 9 9 2 6 2 2 2 2 22/09/2014
50 091817f 9973788278 37 167 81.8 2 2 2 0 1 2 2 2 2 1 1 1 1 1 2 2 2 2 2 5 5 1
51 093556f 9424253550 26 161 52.8 0 2 2 0 4 2 2 2 2 3 2 590 1600 0.509 2 1 3 1 2 2 2 0 0 2 0 1 2 2 11 5 9 5 2 6 1 4 2 2 24/07/2014
52 086490f 32 151 57 1 2 0 4 2 2 2 2 1 2 2 97.5 7.84 501 41.8 2 4.8 1 2 1 1 2 1 0 0 2 0 1 1 2 1 3 7 2 2 2 2 1 20/12/2013 2 11/08/2014
53 099941f 9546787502 27 150 52.7 2 0 3 2 2 2 2 1 2 1 118 1.3 323 0.1 2 1 1 1 1 2 4 0 2 0 1 2 2 1 2 2 2 2 6 2 2 2 31/01/2014
54 131776f 9831715039 30 153 47.6 0 2 2 1 2 2 2 2 2 1 2 35.6 1 1 1 2 2 2 0 0 2 0 2 2 2 2 4 1 2 6 1 2 2 24/08/2014
55 123266f 9489319740 30 144 47.9 1 0 3 2 2 2 2 48.1 1 2 1 1 2 2 0 0 2 0 1 1 2 3 1 5 2 1 2 2 2 2 2 17/08/2014
56 103103f 8015133809 22 164 45.2 0 2 0 3 1 2 8902 1 1 3 2 2 2 1 0 2 0 1 1 2 1 4 1 9 2 6 1 2 2 2 22/05/2014
57 065091f 9835574614 38 155 62.4 2 1 2 0 2 2 2 2 2 1 1 1 17700 473 1 3.2 2 2 2 1 2 2 0 0 2 0 1 1 2 11 3 10 2 1 2 2 2 1 06/02/2014 2 24/08/2014
58 365568f 8900691122 31 166 62.7 6 2 2 0 2 2 2 2 2 1 1 1 23.78 2.6 1 3 2 1 2 2 0 0 2 0 1 2 2 1 5 9 2 2 6 2 2 2 08/04/2013
59 569636b 8900691122 40 150 43.3 0 2 0 3 2 2 2 2 1 2 2 72.4 248 4.5 1 1 1 1 2 1 2 2 1 5 4 2 2 6 2 4 2 2 24/03/2014 2
60 125849f 8900691122 34 149 39.4 3 1 0 2 2 2 2 2 1 2 4.85 1 3.4 2 3 2 1 2 2 0 0 2 0 1 2 11 5 10 2 1 2 2 2 1 04/10/2014
61 159982d 35122258940 24 0 2 2 1 3 59.8 1 1 1 2 2 2 0 0 2 1 2 2 1 4 3 2 6 2 2 2 2 14/08/2014
62 219262f 9.19732E+11 33 163 42.3 2 1 1 2 2 2 2 3 1 203 672 756 0.317 1 1 3 2 1 2 2 0 0 2 0 1 2 2 11 3 8 5 2 2 2 2 2 02/09/2014
63 827838d 9732151583 31 153 50 1 2 0 2 2 2 2 2 1 2 2 25.23 672 406 0.317 1 1 1 1 2 2 2 0 0 2 0 2 2 2 2 4 1 5 2 6 1 2 2 2 20/02/2014
64 182372f 9933524081 32 155 58.2 0 2 2 1 2 2 2 2 2 1 2 3570 3.7 1 2 2 1 2 2 0 0 2 0 1 2 2 11 3 9 2 2 2 2 2 1 04/12/2013 2 14/08/2014
65 268523f 9931589613 17 169 52.5 0 2 2 0 4 2 2 2 2 2 0.48 543 0.1 2.27 1 1 1 1 2 2 2 0 0 2 0 1 1 2 2 4 1 2 6 2 2 2 2 24/08/2014
66 983009c 9894775721 27 158 84 1 2 2 1 4 2 2 2 2 1 2 1 1 2 2 2 2 11 1 1 0 1 1 2 1 5 5 2 2 6 2 2 2 2 07/07/2014
67 312101d 35 155 47.4 4 1 0 3 2 2 2 2 1 2 2 4.5 1 1 1 1 2 2 0 0 2 0 1 2 2 3 1 3 2 2 2 2 2 2 30/06/2010
68 209732f 9735035574 32 158 60 1 2 2 0 3 2 2 2 2 1 2 69.5 0.5 0.1 1 4.5 2 3 2 1 2 1 1 2 1 10 2 1 2 2 2 2 18/07/2014
69 850664d 9608196126 21 157 44.4 0 2 2 1 3 2 2 2 2 2 35.7 2 1 1 2 1 2 2 2 0 1 1 1 2 2 1 1 2 2 2 1 2 4 2 1 18/05/2011 2 29/01/2013
70 207333f 9905165269 28 157 60.7 1 2 2 0 2 2 2 2 2 3 1 2 329 496274 855 1.7 2 2 3 2 1 2 11 0 2 0 1 1 2 7 10 6 1 2 2 2 1 25/07/2013 2 17/08/2014
71 123371d 9865447642 30 4 2 1 2 2 2 2 2 1 1 1 6910 2 2 3 2 1 2 1 2 11 5 10 2 1 1 1
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72 192664d 9474608819 39 162 84 1 2 2 1 4 2 2 2 2 1 4.3 1 2 2 2 2 2 0 0 2 0 1 2 2 1 5 9 2 2 2 2 2 1 16/06/2009 2 30/06/2010
73 143860d 947435747 27 150 38 0 2 1 2 2 2 2 2 2 1.4 1 1 2.6 2 3 1 1 2 2 0 0 2 0 1 2 2 1 3 5 2 1 2 2 4 2 1
74 168668d 9436142985 39 1 1 1 3 2 2 2 2 1 2 500 3.8 2 3 2 1 2 2 0 0 2 0 1 2 2 11 2 9 2 1 2 2 2 2 1 19/09/2008 1 27/05/2009
75 849636c 38 155 36 1 2 1 4 1 2 221 2.3 1 1 1 2 2 0 0 2 0 1 2 2 1 5 9 9 1 2 2 4 2 1 13/07/2009 2 27/04/2010
76 225424d 9933607561 36 147 48 2 1 2 1 4 2 2 2 2 1 70.9 3.2 1 1 2 1 2 2 0 0 2 0 1 2 2 2 4 1 2 6 2 4 2 2
77 213770d 9436168614 38 1 2 1 3 2 2 2 2 1 1 33.7 2 2 4 3 2 2 2 2 2 2 2 2 2 2 11 9 9 2 6 1 2 1 30/05/2008 1 11/07/2008
2 352807c 9791648239 21 150 40 2 2 1 2 2 2 2 2 1 1 1 258 1.27 609 1 4.9 1 1 1 2 2 2 0 0 2 0 1 2 2 1 4 3 2 2 6 1 1 2 2 07/06/2013
79 338257d 9051208170 21 157 59 2 2 2 2 2 2 2 2 2 2 87.4 1.22 509 1 4.6 1 1 1 2 2 2 0 0 2 0 1 2 2 11 5 2 1 2
80 136043d 4171245136 28 2 1 0 2 2 2 2 2 2 86 4.4 1 2 1 1 2 1 1 2 2 4 8 2 2 1 4 2
81 354114d 933134010 28 154 66.3 2 1 1 12 0 4 2 2 2 2 3 2 22.9 1.6 2380 2380 1 1 1 3 0 1 2 2 6 5 1 9 6 2 4 2 2 20/03/2013
82 385829d 9852085847 35 155 73 3 1 2 0 4 2 2 2 2 1 1 20.9 4.4 1 1 1 2 2 1 2 2 1 4 3 2 2 6 2 2 2 07/09/2014
83 191912c 30 157 63.5 2 1 1 2 2 2 2 2 1 6.37 4.7 1 1 2 1 2 2 0 0 2 0 1 2 2 11 5 3 9 2 2 2 4 2 1 26/07/2014
84 068053D 8572283465 18 158 35.5 0 1 2 1 3 2 2 2 2 3 1 1 2640 1081 54.8 4.2 1 1 2 2 2 2 0 0 2 0 2 2 2 6 3 7 5 2 1 2 2 09/07/2012
85 470090D 9474523470 32 153 70 2 1 1 3 2 2 2 2 3 2 102 3770 853 1 4 1 1 1 1 2 1 0 2 1 2 2 7 5 3 9 2 2 2 1 01/09/2014 2 14/03/2014
86 435216D 9954984186 39 147 41.7 3 2 1 3 2 2 2 2 1 1 68.3 4.6 2 1 2 1 2 2 0 0 2 0 1 2 2 11 3 9 2 1 2 2 2 1 01/12/2010 1 23/12/2011
87 495937d 943116738 32 2 2 0 4 2 2 2 2 1 2 195 2 1 4 3 2 2 2 0 0 2 2 2 2 2 11 3 10 9 2 6 1 4 2 1 23/07/2009 1 09/08/2009
88 486913d 9685200303 22 160 30.8 2 2 0 3 2 2 2 2 5 1 2 86.8 2.22 471 1.96 1 2.6 2 4 3 2 2 2 2 2 11 10 9 2 2 1 4 2 1 19/11/2009 1 19/04/2010
89 520836d 35 156 49.3 0 2 2 1 3 2 2 2 2 1 2 2 32.4 2 4.3 1 1 1 1 2 2 0 0 2 0 1 2 2 1 2 2 2 2 2
90 551046d 19436118019 39 151 55.8 2 2 2 0 4 2 2 2 2 1 2 2 4.5 1 1 2 1 2 2 0 0 2 0 1 2 2 3 1 1 2 2 1 2 2 2 20/08/2014
91 424771d 9748906049 37 151 52.8 1 2 1 3 2 2 2 2 1 2 73.2 4.1 2 3 2 2 0 0 2 0 1 2 2 11 3 10 2 2 2 1 2
92 698040d 9234431261 23 154 56 2 2 1 3 2 2 2 2 140.1 5430 1300 155.7 3.3 1 2 1 2 2 2 0 0 2 0 1 2 2 11 6 5 2 6 2 1 2 2 2 09/09/2014
93 705794b 9444236576 33 150 96.4 2 1 1 3 2 2 2 2 1 2 11.2 4.6 1 1 1 1 2 2 0 0 2 0 1 2 2 2 2 3 2 2 6 2 4 2 2 2 08/09/2014
94 814629c 9443164847 28 1 2 0 4 2 2 2 2 1 2 9.84 1.66 520 1 1 1 1 2 1 2 1 2 2 1 2 6 2 2
95 648872d 9346815702 25 150 39.2 0 2 2 0 4 2 2 2 2 2 1 4.9 1 1 3 2 2 2 0 0 2 0 2 2 2 11 5 1 9 2 5 1 2 2 2 23/08/2014
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96 754678d 36 1 2 2 0 3 3 2 2 138 420 6142 1 1 3 2 1 2 2 7 1 5 1 2 12/02/2011
97 574461d 9933757382 28 149 51 1 2 1 48 1 1 2 2 2 2 2 1 149 5.5 676 1 1 2 2 1 2 1 1 2 2 5 10 2 2 2 2 2 1 01/02/2010
98 829356d 9774156903 17 160 53 2 2 0 3 2 2 2 2 1 2 2.36 1.48 1 5 1 1 1 2 1 2 6 2 2 2 2 17/06/2011
99 136529f 9494032611 34 155 64 1 2 2 0 3 2 2 2 2 21.2 1 4.1 1 1 2 1 2 2 0 0 2 0 1 2 2 11 5 3 2 2 6 2 2 2 2 17/08/2014
100 498835c 26 0 2 2 1 4 2 2 1 1 2 1 2 1 0 0 2 0 2 2 2 8 3 4 6 2 1 2 1 03/08/2004 2 15/03/2008
101 228700d 9790175645 39 155 62 2 1 1 3 2 2 2 2 1 2 4.4 1 1 2 1 2 2 0 0 2 0 1 2 2 2 5 3 2 2 4 2 2 2 06/08/2014
102 248993d 9790175645 35 146 66 0 2 1 2 2 2 2 1 1 2 2 1690 3.6 1 1 2 1 2 2 0 0 2 0 1 2 2 2 4 3 2 2 6 2 4 2 2 2 17/08/2014
103 203506d 9732330980 38 63 1 2 1 2 2 2 2 1 1 1 5000 3.6 2 1 2 1 2 2 0 0 2 0 2 2 2 11 9 2 1 2 1 4 2 1 01/12/2008 1 10/04/2010
104 260168d 13 30 0 2 2 3 3 2 2 2 2 3 197 30000 2040 4.88 2 3.3 1 2 1 2 2 2 0 0 2 0 2 2 2 7 5 3 5 2 6 1 1 2 2 2 08/05/2014
105 286097d 9.19995E+11 35 157 57.8 2 2 2 1 4 2 2 2 2 365 1 1 2 1 2 2 2 2 3 1 4 2 2 1 2 2 2 23/07/2014
106 311692d 26 2 2 1 2 2 2 2 2 1 1 413 1.03 534 1 1 3.6 1 3 2 1 2 2 0 0 2 0 1 2 2 11 3 9 9 2 6 2 4 2 1 24/10/2008
107 415338d 9788696882 16 157 45 2 2 1 2 2 2 2 2 99.2 14700 2733 7.04 3.6 1 3 3 2 2 2 0 0 2 0 1 2 2 7 5 9 5 2 6 1 1 2 16/08/2010 2
108 201324d 29 147 34 2 1 1 3 2 2 2 2 2 3220 0.95 646 1 2 3.4 2 1 2 1 2 2 0 0 2 0 1 1 2 7 5 10 9 1 3 2 2 1 14/10/2009 2 30/06/2010
109 979084c 9.19044E+11 37 155 62 3 1 2 16.7 1 1 2 1 2 2 1 2 2
110 451494d 9647597841 19 2 2 1 2 2 2 2 2 67 654 3586 132 4.4 1 4 3 2 2 2 0 0 2 0 2 2 2 6 3
111 926875c 35 160 64 3 1 1 2 2 2 2 2 1 1 3.9 1 2 2 1 2 1 2 2 1 4 3
112 452338d 9434867897 40 148 59 1 2 1 2 2 2 2 1 1 2 916 1 4.1 2 2 2 1 2 2 0 0 2 0 1 2 2 11 3 10 2 1 6 2 4 2 2 2 25/07/2014
113 494308d 94747520 35 156 42.3 2 1 1 2 2 2 2 2 1 1 2 1348 1 2.2 1 1 2 1 2 2 0 0 2 0 1 2 2 11 3 9 2 2 2 2 2 1 25/06/2013 2 18/07/2014
114 390247d 9447838851 34 147 70 1 2 1 2 1 1 2920 1 1 2 1 2 2 0 0 2 0 1 2 2 1 3 8 2 2 2 2 2 1 01/06/2012 1 03/06/2012
115 755137d 944650885 18 164 50.4 2 2 0 3 2 2 2 2 3 2 35.2 1.19 1031 97.02 2 4.9 1 2 1 2 2 2 0 0 2 0 1 2 2 6 4 5 2 6 1 2 2 08/08/2014
